A Link between Virulence and Homeostatic Responses to Hypoxia during Infection by the Human Fungal Pathogen Cryptococcus neoformans

Cheryl D. Chun[©], Oliver W. Liu[©], Hiten D. Madhani^{*}

Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California, United States of America

Fungal pathogens of humans require molecular oxygen for several essential biochemical reactions, yet virtually nothing is known about how they adapt to the relatively hypoxic environment of infected tissues. We isolated mutants defective in growth under hypoxic conditions, but normal for growth in normoxic conditions, in *Cryptococcus neoformans*, the most common cause of fungal meningitis. Two regulatory pathways were identified: one homologous to the mammalian sterol-response element binding protein (SREBP) cholesterol biosynthesis regulatory pathway, and the other a two-component-like pathway involving a fungal-specific hybrid histidine kinase family member, Tco1. We show that cleavage of the SREBP precursor homolog Sre1—which is predicted to release its DNA-binding domain from the membrane—occurs in response to hypoxia, and that Sre1 is required for hypoxic induction of genes encoding for oxygen-dependent enzymes involved in ergosterol synthesis. Importantly, mutants in either the SREBP pathway or the Tco1 pathway display defects in their ability to proliferate in host tissues and to cause disease in infected mice, linking for the first time to our knowledge hypoxic adaptation and pathogenesis by a eukaryotic aerobe. SREBP pathway mutants were found to be a hundred times more sensitive than wild-type to fluconazole, a widely used antifungal agent that inhibits ergosterol synthesis, suggesting that inhibitors of SREBP processing could substantially enhance the potency of current therapies.

Citation: Chun CD, Liu OW, Madhani HD (2007) A link between virulence and homeostatic responses to hypoxia during infection by the human fungal pathogen Cryptococcus neoformans. PLoS Pathog 3(2): e22. doi:10.1371/journal.ppat.0030022

Introduction

Microbial pathogens must overcome numerous obstacles to infection to successfully colonize a host. It has been hypothesized that one of these barriers is hypoxia. Oxygen levels in mammalian tissues are found to be considerably below atmospheric levels [1-3]. Moreover, inflammation, thrombosis, and necrosis associated with infection are thought to lead to increased degrees of hypoxia [4,5]. While many pathogenic microbes are facultative or obligate anaerobes, a number of major bacterial and fungal pathogens are classified as obligate aerobes. Among these are the bacterial species Neisseria meningiditis, Pseudomonas aeruginosa, Mycobacterium tuberculosis, and Bordetella pertussis. In N. meningitidis and B. pertussis, mutants in homologs of the Escherichia coli hypoxiaresponsive regulator Fnr are attenuated in experimental animals, consistent with a role for hypoxic adaptation in virulence [6,7]. Microarray analysis indicates that in N. meningitidis, Fnr activates genes encoding proteins involved in sugar transport/utilization, cytochromes, and denitrification enzymes that may promote usage of nitrate and nitrite instead of oxygen as a terminal electron acceptor during oxidative phosphorylation of ADP [6]. In contrast, a M. tuberculosis mutant defective in a nitrate reductase required for hypoxic growth in vitro was not attenuated in vivo [8].

In the fungal kingdom, some pathogens, such as *Candida albicans*, are capable of anaerobic fermentation in rich medium, but even in these species, molecular oxygen is thought to be essential for synthesis of ergosterol, NAD, and

heme, molecules likely to be scarce in the host milleu and therefore difficult to obtain. In bacterial pathogens, NAD and heme synthesis can be catalyzed by alternative, oxygen-independent pathways, and sterol synthesis is thought to not exist [9,10]. Therefore, hypoxia should in principle be a far more significant challenge for fungal than bacterial pathogens; yet, it is unknown for any pathogenic fungi whether adaptation to hypoxia is necessary for virulence, and there is currently little information on the nature of corresponding adaptive mechanisms. In the best-studied human pathogenic fungus, *C. albicans*, one adaptive mechanism may involve the pleiotropic virulence regulator Efg1. Efg1 was recently shown in hypoxia to promote the synthesis of unsaturated fatty acids and to repress filamentous growth,

Editor: Scott G. Filler, David Geffen School of Medicine, United States of America

Received November 7, 2006; Accepted December 29, 2006; Published February 23, 2007

Copyright: © 2007 Chun et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: bHLH, basic helix-loop-helix; NAT, nourseothricin; NEO, neomycin; ORF, open reading frame; RT-QPCR, reverse transcription quantitative PCR; SAM, Significance Analysis of Microarrays; SCAP, SREBP cleavage-activating protein; SREBP, sterol-response element binding protein; YNB, yeast nitrogen base; YPD, yeast extract peptone dextrose

- * To whom correspondence should be addressed. E-mail: hiten@biochem.ucsf.edu
- These authors contributed equally to this work.

Author Summary

Opportunistic environmental pathogens adapt to hostile conditions within the host to cause disease. We describe two pathways in the pathogenic fungus Cryptococcus neoformans that are both necessary for adaptation to hypoxia and required for its virulence. One pathway uses a pathway homologous to the mammalian sterolresponse element binding protein (SREBP) pathway to activate genes involved in sterol biosynthesis in response to low oxygen levels, while the other pathway involves the two-component hybrid histidine kinase protein Tco1. Mutant strains containing deletions of genes encoding components in either of these pathways were found to be less virulent in experimental mouse models. This study suggests that this pathogenic fungus experiences low levels of oxygen in the mammalian host, and that adaptation to these conditions is important for infection. Targeting components of the hypoxia response could yield more effective treatments for C. neoformans infections, which cause a large fraction of HIV/AIDSrelated deaths worldwide. Notably, we find that mutants in the SREBP-like pathway are a hundred times more sensitive than wildtype cells to the widely used antifungal drug fluconazole.

whereas in normoxia, Efg1 promotes filamentation, activates glycolytic gene expression, and represses genes whose products promote oxidative metabolism [11,12].

Recent work in the nonpathogenic ascomycete fission yeast Schizosaccharomyces pombe has shown that a pathway homologous to the mammalian sterol-response element binding protein (SREBP) pathway is important for hypoxic adaptation [13,14]. In the mammalian pathway, sterols negatively regulate the release of a transcriptionally active, soluble DNA-binding portion of the SREBP transmembrane precursor protein through regulation of two proteolytic steps, one lumenal and one intramembrane [15]. Proteins required for cleavage of the mammalian SREBP precursor include SREBP cleavage-activating protein (SCAP), Insig, Site-1-protease, and Site-2-protease [15]. SCAP interacts with SREBP to regulate its cleavage and contains a domain thought to directly bind sterols, Insig negatively regulates SCAP, Site-1protease is a member of the Kex2 family of lumenal proteases, and Site-2-protease is a metalloprotease responsible for intramembrane cleavage of the precursor [15]. The S. pombe SREBP-like pathway controls the expression of genes involved in ergosterol synthesis, and the available evidence suggests that hypoxia signals the SREBP-like pathway by reducing sterol levels, which, in turn, promotes the processing of the SREBP homolog, Sre1 [13,14].

One way of assessing whether a particular property of a pathogen is involved in virulence is to identify mutants defective in that property and then assess the pathogenicity of that mutant in an animal model of infection. For example, early work in *C. albicans* demonstrated that an engineered nonfilamentous mutant displayed greatly reduced virulence, providing initial evidence for a link between filamentous growth and virulence [16].

We have used the genetically tractable haploid human pathogenic yeast *Cryptococcus neoformans* to probe the role of hypoxic adaptation in fungal virulence. *C. neoformans* is an obligate aerobe that causes meningitis and other infections in immunocompromised individuals [17]. It exists as four distinct serotypes that are classified into three groups: *C. neoformans var grubii* (serotype A), *C. neoformans var gatii*




Figure 1. Mutants in SREBP Pathway and Tco1 Are Sensitive to Hypoxia Growth in normoxic and hypoxic conditions. Cultures diluted to $OD_{600nm} = 0.6$ were diluted serially in 10-fold increments prior to being spotted onto YPD plates. Plates were incubated in normoxic or hypoxic (controlled atmosphere chamber; less than 0.2% oxygen) conditions in the dark at 37 °C. Top and bottom panels are from the same plates, middle panels are from plates grown under the same conditions. WT, wild-type.

doi:10.1371/journal.ppat.0030022.g001

(serotypes B and C), and *C. neoformans var neoformans* (serotype D). Together, these groups are estimated to cause between 15% and 40% of the 3.1 million annual deaths of individuals with HIV/AIDS; serotype A isolates are associated with the vast majority of infections in patients both positive and negative for HIV [18,19]. For the studies described below, we used the clinical serotype A isolate, H99.

Results/Discussion

As part of an ongoing gene disruption project, we have generated targeted knockouts of ~1,200 C. neoformans genes (O. Liu, E. Chow, and H. Madhani, unpublished data). We screened this collection for mutants that displayed sensitivity to hypoxia, and we report here the characterization of four genes required for hypoxic adaptation. Among these are homologs of proteins that act in the mammalian SREBP pathway. We identified hypoxia-sensitive mutants in cryptococcal homologs of SREBP, Site-2-protease, and SCAP, which we respectively name Sre1, Stp1, and Scp1 (Figures 1 and 2A). Significantly, the basic helix-loop-helix (bHLH) DNA-binding domain of Sre1 contains a conserved tyrosine residue (Figure 2B) that is specific to the SREBP family of bHLH transcription factors [20]. We generated two independent knockouts of the genes encoding Sre1 (sre1 Δ -1 and sre1 Δ -2), Stp1 $(stp1\Delta-1 \text{ and } stp1\Delta-2)$, and Scp1 $(scp1\Delta-1 \text{ and } scp1\Delta-2)$, and in each case, independent disruptions produced a hypoxiasensitive phenotype (Figure 1). Re-introduction of SRE1 into the $sre1\Delta$ -2 strain restored sensitivity to levels similar to that of wild-type (Figure S1A).

As mentioned in the Introduction, it has been shown that in *S. pombe*, homologs of SREBP and SCAP are critical for survival under hypoxic conditions [13,14]. Our identification of a similar role for these components in the basidiomycete *C.*




Figure 2. Predicted Protein Domains for SREBP Pathway Component Orthologs and Tco1 Histidine Kinase Family Members

(A) Protein domains as predicted by SMART (http://smart.embl-heidelberg.de) for *C. neoformans* Sre1, Scp1, and Stp1. Transmembrane segments for Sre1 were predicted using MEMSAT3 (http://bioinf.cs.ucl.ac.uk). Arrowhead indicates site of 3×FLAG insertion into Sre1. bHLH, bHLH DNA-binding domain; peptidase, peptidase M50 family domain.

(B) ClustalW sequence alignment between *C. neoformans* Sre1 and its orthologs in *C. albicans, Ustilago maydis, S. pombe,* and human (SREBP-1A), depicting a portion of the predicted DNA-binding domain. All five contain a conserved tyrosine residue (indicated by asterisk) specific to the SREBP family of bHLH transcription factors.

(C) Domains as predicted by SMART for Tco1 homologs. *C. neoformans* Tco1, and orthologs to Tco1 from *B. dermatiditis*, *H. capsulatum*, *C. albicans*, and *Neurospora crassa*. HATPase, histidine kinase ATPase domain; HisKA, histidine kinase A domain; REC, cheY-like homologous receiver domain. doi:10.1371/journal.ppat.0030022.g002

neoformans suggests broad conservation of this adaptive mechanism across the fungal kingdom. Curiously, examination of available databases yielded no clear homolog of Site-2protease in the *S. pombe* genome sequence or in the genomes of fungi other than C. neoformans, suggesting that either this component of the SREBP pathway does not exist in those species or has diverged to a point where it is no longer recognizable. We were also unable to identify a homolog of Insig in C. neoformans, yet a clear homolog exists in S. pombe [14]. Finally, no ortholog of Site-1-protease is apparent in either genome; this function may be carried out by homologs of Kex2 present in each genome. Notably, the C. albicans protein most similar to Sre1 is Cph2 (Figure 2B), a transcriptional regulator previously shown to regulate hyphal development [21]. Although Cph2 binds to DNA elements similar to those bound by SREBP in mammalian cells [21], it is unclear whether it functions in an SREBP-like pathway.

In addition to components of the Srel pathway, we identified a hypoxia-sensitive mutant in Tcol, a member of a highly conserved family of fungal-specific histidine kinases (Figure 1). Tcol has been shown previously to be required for virulence, yet the basis for this requirement has not been elucidated [22]. Paradoxically, Tcol negatively regulates the

expression of a known virulence factor, melanin formation, and, redundantly with Tco2, positively regulates the HOG MAPK pathway, which is dispensable for virulence [22]. We generated a second independent knockout of TCOI, which confirmed the hypoxia sensitivity of this mutant. Reintroduction of TCOI into the $tcoI\Delta$ -I strain rescued its hypoxia-sensitive phenotype (Figure S1A). Significantly, a $tcoI\Delta$ $sreI\Delta$ double knockout is more sensitive to hypoxia than either single mutant, indicating that Tco1 functions in a pathway parallel to the SREBP pathway (Figure 1).

Homologs of Tco1 with diverse functions have been described in a number of ascomycete fungi (Figure 2C). One of these, Drk1, has been recently shown in the human fungal pathogen *Blastomyces dermatiditis* to be required for temperature-regulated dimorphism and pathogenesis; its potential role in hypoxic adaptation was not reported [23]. A close homolog of Drk1 exists in *Histoplasma capsulatum* that is also involved in temperature-regulated dimorphism [23]. It was proposed that Drk1 is a transmembrane sensor that contains an N-terminal domain containing two transmembrane domains. However, analysis of Drk1 using the SMART database (Figure 2C) indicates that, instead, it contains a series of six tandem HAMP domains characteristic of the




Figure 3. Phenotypic Characterization of Mutants in the SREBP Pathway and in TCO1

(A) Growth in YNB medium at 37 $^{\circ}$ C. Growth was monitored via OD₆₀₀ measurements. Data shown are an average of three independent cultures for each strain, and error bars represent standard deviations (SD).

(B) Capsule assays. Above, capsule synthesis was induced in wild-type (WT), $sre1\Delta-1$, and $tco1\Delta-1$ strains, and subsequently visualized using India ink staining. Images were taken at $160\times$ magnification. Below, quantification of the ratio of capsule diameter to cell diameter for capsule-induced cells from the indicated strains. Data shown represent the mean \pm SD, $n \ge 30$. p-Values (asterisks) were derived using Student's t-test.

(C) Melanin assays. The indicated strains were grown to saturation and spotted onto L-DOPA–containing medium. The plates were then cultured at 37 °C in the dark.

doi:10.1371/journal.ppat.0030022.g003

fungal-specific subfamily of histidine kinases, and is therefore more likely to be a soluble signaling protein. HAMP domains are found in a large number of signaling proteins, and, in one of these proteins, forms a four-helix bundle that may transduce signals via rotation of the helices [24]. In contrast to dimorphic fungi such as *B. dermatiditis, Coccidioides immitis,* and *H. capsulatum, C. neoformans* grows as a yeast both in the environment and in the host, suggesting a distinct role in virulence for Tco1 compared with that of its ascomycete orthologs.

As with mutants in the Sre1 pathway, cells lacking Tco1 grow normally at 37 °C in minimal (yeast nitrogen base [YNB]) or rich (yeast extract peptone dextrose [YPD]) medium under normoxic conditions, suggesting that their

defects in virulence are not due to a general growth defect (Figure 3A). We examined two characteristics believed to be important for virulence in C. neoformans, its polysaccharide capsule and its ability to melanize. We observed no gross defect in the formation of the polysaccharide capsule in any of the mutants; however, quantification of the ratios of capsule diameters to cell diameters did reveal rather subtle defects in the $sre1\Delta$ and $tco1\Delta$ mutants (Figure 3B). Mutants in the SREBP pathway display a slight defect in melanization under normoxic conditions and, as previously reported, mutants in TCO1 display hypermelanization (Figure 3C). A $tco1\Delta$ $sre1\Delta$ double knockout also displays a slight defect in melanization. The complemented strains $sre1\Delta-2 + SRE1$ and




Figure 4. FLAG-Sre1 Is Processed in Low Oxygen Conditions

Proteins extracts from wild-type and two independent cultures of *FLAG-SRE1* grown in normoxic and hypoxic (bubbling mixed gas into flasks; 0.2% oxygen) conditions were fractionated by SDS-PAGE and immunoblotted with antibodies against the FLAG epitope. Immunoblotting with antibodies against the cyclin-dependent protein kinase PSTAIRE was used to control for variation in loading. doi:10.1371/journal.ppat.0030022.g004

 $tco1\Delta$ -1 + TCO1 displayed wild-type levels of melanization (Figure S1B).

In fission yeast, processing of Sre1 occurs in response to hypoxia [14]. To test whether this was the case in *C. neoformans*, we used homologous recombination to precisely insert three tandem copies of the FLAG epitope tag into the Sre1 coding sequence upstream of the predicted DNA-binding domain (Figure 2A). We assessed the processing of the protein by immunoblotting SDS-PAGE-fractionated extracts that were prepared from cells grown under normoxic versus hypoxic conditions (Figure 4). In response to hypoxia, a lower molecular weight form of Sre1 could be detected.

In mammalian cells, cleavage releases SREBP from endoplasmic reticulum and Golgi membranes, allowing it to then enter the nucleus and induce transcription of genes. It therefore seemed likely that hypoxia-dependent cleavage of Sre1 in *C. neoformans* would correlate with the up-regulation of hypoxia-regulated genes.

To test this hypothesis, we used whole-genome microarray-based transcriptional profiling. We found that that the response of wild-type cells to hypoxic conditions involved changes in the levels of 347 transcripts. These included the up-regulation of homologs of genes involved in stress and carbohydrate uptake/metabolism, similar to what has previously been reported in *Saccharomyces cerevisiae* [25], *S. pombe* [13], and *C. albicans* [11]. Select categories are presented in Table 1, and the full dataset is available in Table S3. In *S. cerevisiae*, *S. pombe*, and *C. albicans*, genes encoding respiratory proteins are down-regulated in response to hypoxia. In

contrast, in *C. neoformans*, these genes are up-regulated, perhaps because it is an obligate aerobe. Similar to what has been described in other fungi, transcripts of genes involved in sterol, heme, and fatty acid metabolism are also up-regulated in *C. neoformans* in response to low oxygen conditions, including *SRE1* and homologs to the genes *ERG1*, *ERG3*, *ERG5*, *ERG25*, *HEM3*, *HEM13*, *SCS7*, *SUR2*, and *OLE1*. Categories of genes down-regulated in response to hypoxia include proteins involved in translation, vesicle trafficking, and cell wall and capsule synthesis (*CAP64* and *CAP60*).

A comparison in expression levels between wild-type and $sre1 \triangle -2$ grown under normoxic conditions identified only two genes as having significant differences in expression between the two strains: SRE1 itself and ERG5, a C-22 sterol desaturase involved in sterol synthesis (Table S5). While ERG5 requires Sre1 for full expression under normoxic conditions, it does not require Sre1 for its induction under hypoxic treatment (Figure 5B).

We determined that of the 347 genes that were induced or repressed in wild-type by hypoxic treatment, 54 required Srel for their induction or repression (Table S4, summarized in Figure 5A). Of the subset denoting hypoxia-induced genes with weaker induction in $srel \Delta - I$ than in wild-type, the greatest difference in expression between wild-type and mutant were in the two genes ERGI and ERG3. Strikingly, these genes encode for homologs to oxygen-dependent ergosterol biosynthetic pathway enzymes: ERGI encodes squalene epoxidase and ERG3 encodes C-5 sterol desaturase. Both of these enzymes require molecular oxygen for their catalytic activities. We confirmed these data using reverse transcription quantitative PCR (RT-QPCR) analysis (Figure 5B).

We also performed similar experiments in strains lacking Tco1. In contrast to mutants in Sre1, the $tco1\Delta$ mutant did not show detectable defects in the regulation of mRNA levels for any of the 347 hypoxia-responsive genes (unpublished data). Thus, this kinase appears to function independently of transcription to mediate hypoxic adaptation, and we speculate that it may act post-transcriptionally. The phenotype of $tco1\Delta$ is specific in that strains containing disruptions of the other five histidine kinases encoded by the *C. neoformans* genome do not demonstrate sensitivity to hypoxia (C. Chun, unpublished observations).

Having identified mutants in two apparently distinct regulatory pathways required for hypoxic adaptation, we tested their effects on growth and virulence in infected experimental mice. To assess the effects on proliferation and survival in the host, we infected mice with 1:1 mixtures of wild-type and mutant cells and examined their relative representations in various tissues after a fixed period of time. Two infection routes were tested, intravenous and intranasal.

In the intravenous competition experiments, animals were sacrificed 10 d post-infection and the proportions of mutant cells in the lungs, brains, and spleens were determined. As shown in Figure 6A, knockout mutants in SRE1, SCP1, STP1, and TCO1 showed a dramatic and reproducible defect in their ability to proliferate in lungs relative to wild-type cells. While they represented $\sim\!50\%$ of the cells in the inoculum, the mutant cells made up only $\sim\!5\%$ of the cells recovered from the lungs. A more moderate and variable defect was observed in the brains and spleens. As a control, we co-infected wild-

 Table 1. Select Categories of Genes Induced/Repressed by C. neoformans in Response to Hypoxia

| Transcription Several metabolism CHOL 25977 CHOMG, 022277 SHOCK Protein required for normal intracellular 2.98 1.00 1 | Transcript Class | Functional Category | Microarray Oligo Number | Broad Annotation | Gene Name | Putative Function | C. neoformans -/+ 02 | S. cerevisiae -/+ 02 | C. albicans -/+ 02 | 5. pombe -/+ 02 |
|--|-----------------------------|-----------------------------|-------------------------------|---------------------|----------------|---|-------------------------|-------------------------|-----------------------|--------------------|
| CHO, 2935 CHO, 2945 CHO, 2947 CHO, 2444 ERG232 CLO, 2475 CHO, 2444 CHO, 2452 CHO, 2444 ERG232 CLS, sten) desaturase 2.72 3.12 CHO, 2475 CHO, 2675 CH | Up-Regulated Transcripts | Sterol metabolism | CNO_2597 | CNAG_03227.1 | ARV1 | Protein required for normal intracellular sterol distribution and for sphingolipid metabolism | 2.98 | 1.00 | | |
| CHOL 3377 ChMCG 008241 Encol C-22 Mercel (destitutiase 2.95 1.12 CHOL 3377 ChMCG 008141 ERG38 C-2 sterol destitutiase 2.77 3.12 CHOL 3897 CHMCG 008141 ERG38 C-5 sterol destitutiase 2.72 3.12 CHOL 3897 CHMCG 008241 SRE1 DHL HEM13 CORPORADY (MISSINGER) 2.60 2.0.20 CHOL 3897 CHMCG 008241 SRE1 DHL HEM13 CORPORADY (MISSINGER) 2.40 1.14 CHOL 3897 CHMCG 008241 SURZ SPHIngolipid alpha-Hydroxylase 2.40 1.14 CHOL 3897 CHMCG 008241 SURZ Sphingolipid alpha-Hydroxylase 2.40 1.14 CHOL 3897 CHMCG 008241 SURZ Activity acid destitutase 2.14 1.14 CHOL 3898 CHMCG 008241 SURZ Paler's Pittyly acid destitutase 2.17 0.17 CHOL 3899 CHMCG 008241 SURZ Paler's Pittyl acid destitutase 2.17 0.17 CHOL 3899 CHMCG 008241 CHMCG 008241 SPF1301 | | | CNO_2935 | CNAG_01737.1 | ERG25 | Probable c-4 methyl sterol oxidase | 5.29 | 2.32 | 1.6 | 3.14 |
| CMO, 5817 CMAG, 095191 SEGGSB CS sterol destutnose 277 3.12 CMO, 5817 CMAG, 096041 SEGGSB CSS SAMINATE 2.00 20.20 CMO, 5817 CMAG, 024501 HEM13 CHARDARE 2.44 1.05 CMO, 1889 CMAG, 024501 PCT ARMERIA CAPAC, 04860 2.04 1.05 CMO, 2879 CMAG, 004571 PCT ARMERIA Phytocomenhidase 2.40 1.14 CMO, 2879 CMAG, 001641 PCT ARMERIA Phytocomenhidase 2.05 1.14 CMO, 2872 CMAG, 0017501 SPST/201 CAPAC, 001867 1.04 1.14 CMO, 2873 CMAG, 0017501 SPST/201 CAPAC, 001867 1.04 1.14 CMO, 2873 CMAG, 0017501 SPST/201 CAPAC, 001867 1.04 1.04 CMO, 2873 CMAG, 0017501 SPST/201 CAPAC, 001867 1.04 1.04 CMO, 2874 CMAG, 0017501 CAPAC, 0017602 CAPAC, 0017602 CAPAC, 0017602 1.04 1.04 | | | CNO_444 CNO_3577 | CNAG_06644.1 | ERG1 ERG502 | Squalene epoxidase-like protein C-22 sterol desaturase | 3.98 2.76 | 1.27 | 2.2 | 2.76 |
| CNO. 3817 CNAG. 6984.1 SRE1 bHLH transcription factor 3.39 CORD. 200.0 CNO. 2879 CNAG. 02460.1 HEM13 Chylocopphymose 2.40 1.14 CNO. 2879 CNAG. 01721.1 HEM13 Chylocopphymose 2.40 1.14 CNO. 2879 CNAG. 01721.1 HEM13 Chylocopphymose 2.40 1.14 CNO. 6216 CNAG. 0194.1 YRC1 Acethyl-CoA expt. CoA | | | CNO_4325 | CNAG_00519.1 | ERG3-B | C-5 sterol desaturase | 2.72 | 3.12 | 2.4 | 3.92 |
| CNO_1899 CNAG_0257.1 HEM13 Copport/polymogenee 2.60 20.20 CNO_1954 CNAG_072.11 HEM13 Copport/polymogenee 2.41 1.05 CNO_2959 CNAG_072.12 HEM13 Copport 2.41 1.05 CNO_2950 CNAG_0714 YPC Aphingolipid alpha-hydroxylase 2.40 1.14 CNO_2950 CNAG_0834.1 SVRZ Aphingolipid alpha-hydroxylase 2.40 1.14 CNO_2972 CNAG_0837.1 CNAG_0837.1 <td< th=""><th></th><th></th><td>CNO_5817</td><td>CNAG_04804.1</td><td>SRE1</td><td>bHLH transcription factor</td><td>3.09</td><td></td><td></td><td>4.75</td></td<> | | | CNO_5817 | CNAG_04804.1 | SRE1 | bHLH transcription factor | 3.09 | | | 4.75 |
| CNO_2879 CNAG_0277.1.1 FIRMS Phylosophied sphrahodysee 9.44 1.0.5 CNO_2879 CNAG_0277.1.1 FIRMS Phylosophied sphrahodysee 9.44 1.0.4 CNO_2879 CNAG_0280.1 PDT1 Adalaine phytocennidase 2.76 1.42 CNO_2877 CNAG_0187.1 YRC1 Adalaine phytocennidase 2.76 1.14 CNO_2877 CNAG_0187.1 VRD Adalaine phytocennidase 8.21 0.17 CNO_2877 CNAG_0187.1 OLD Debt-1.2 fatty acid desaturase 3.22 0.17 CNO_2891 CNAG_0186.1 CNAG_0186.2 CNAG_0186.2 2.46 0.17 CNO_2892 CNAG_0222.1 CNAG_0186.2 Adose L-epimerase 2.17 0.73 CNO_2991 CNAG_0222.1 CNAG_0222.1 CNAG_0222.1 CNAG_0222.1 Adose L-epimerase 3.74 0.73 CNO_1892 CNAG_0222.1 CNAG_0 | | Heme metabolism | CNO_1809 | CNAG_02460.1 | HEM13 | Coproporphyrinogen oxidase | 2.60 | 20.20 | | 14 |
| CNO_4399 CNMG_00491 POTI Acetyl-CoA acetyl transferase 2.40 1.14 CNO_6599 CNMG_00441 YPC1 Alkilline phytoceanidase 2.75 1.42 CNO_6599 CNMG_05972 SURZ Alkilline phytoceanidase 2.75 1.42 CNO_65972 CNMG_06871 SURZ Phytopane Putp acid desaturase 8.21 3.49 CNO_5839 CNMG_06871 CNRG_06860 Dela-12 fathy acid desaturase 2.22 0.73 CNO_4008 CNMG_07571 VMR099C Aldoes 1-epimerase 2.17 0.73 CNO_4008 CNMG_06271 VMR099C Aldoes 1-epimerase 2.17 0.73 CNO_189 CNMG_06221 VMR099C Aldoes 1-epimerase 2.17 0.73 CNO_189 CNMG_06221 CNMG_06921 LCLC 1.00 0.73 CNO_189 CNMG_06221 CNMG_06922 Aldoes 1-epimerase 2.17 0.73 CNO_189 CNMG_06221 CNMG_06922 Alcohophate phosphorylane gray 2.17 0.73 CNO_188 CNMG_06921 <th></th> <th>Sphingolipid/fatty</th> <td>CNO_1954</td> <td>CNAG_01/21.1</td> <td>SCS7</td> <td>nydroxymetnylbilane synthase Sphingolipid alpha-hydroxylase</td> <td>9.94</td> <td>1.94</td> <td></td> <td>2.14</td> | | Sphingolipid/fatty | CNO_1954 | CNAG_01/21.1 | SCS7 | nydroxymetnylbilane synthase Sphingolipid alpha-hydroxylase | 9.94 | 1.94 | | 2.14 |
| CNO 699 CNAG, 010441 YPCT Alloline phytoceramidase 276 1.42 CNO 6216 CNAG, 2015A1 Spinganine hydroxylase 3.94 3.49 CNO 5772 CNAG, 2047A1 SUBDSW Spinganine hydroxylase 3.73 0.17 CNO 5839 CNAG, 2047A1 OLEA Detack of large and desaturase 3.13 0.17 CNO 591 CNAG, 2012G1 YMB09SQ Aldoxe Lepimerase 4.61 0.73 CNO 1991 CNAG, 2024A1 CNED3600B Detack of Lepimerase 4.61 0.73 CNO 1991 CNAG, 2024A1 CNED3600B Clear of Lepimerase 4.61 0.73 CNO 1991 CNAG, 2024A1 CNED360B Clear of Lepimerase 4.85 0.69 CNO 1919 CNAG, 2024A1 CNED360B Clear of Lepimerase 4.85 0.73 CNO 1919 CNAG, 2024A1 CNED360B Clear of Lepimerase 4.85 0.69 CNO 1910 CNAG, 2024A1 CNAG, 2024A1 CNAG, 2024A1 CNAG, 2024A1 CNAG, 2024A1 CNAG, 2024A1 CNAG, 2024A1< | | acid metabolism | CNO 4309 | CNAG 00490.1 | POT1 | Acetyl-CoA acetyl transferase | 2.40 | 1.14 | | |
| CNO_2216 CNAG_08841 SIRP2 Sphinganine Indrowlase 3.94 3.49 CNO_2573 CNAG_04757.1 Y8L095W Putative Intersersase 8.21 0.17 CNO_2591 CNAG_04757.1 OLED Double 12 fish acid desaturase 2.22 0.17 CNO_2591 CNAG_0156.1 CNBD360-8 Desta-12 fish acid desaturase 4.61 0.73 CNO_2400 CNAG_0262.1 YMR095C Aldose Leppinease 4.61 0.73 CNO_1991 CNAG_0262.1 YMR095C Aldose Leppinease 4.61 0.73 CNO_1992 CNAG_0262.1 CNR0300 Glucose-fructose oxidoreductase 4.85 0.73 CNO_1893 CNAG_0262.1 CNR300 Glucose-fructose oxidoreductase 4.85 0.69 CNO_1894 CNAG_0273.1 CNR300 Glucose-fructose oxidoreductase 4.85 0.69 CNO_1895 CNAG_0273.1 CNR300 Lourances, sucrose-fructose 11.89 0.73 CNO_1805 CNAG_0273.1 CNR300 Lourances, sucrose-fructose 4.85 0.69 < | | | CNO_699 | CNAG_01044.1 | YPC1 | Alkaline phytoceramidase | 2.76 | 1.42 | | |
| CNO_5873 CNAG_04757.1 YBLOSSW Putative thioesterase 8.21 0.17 CNO_5839 CNAG_04657.1 CLRD_5607.2 OLEP 5 fitty acid desaturase 2.12 0.73 CNO_5839 CNAG_0156.1 CNB0560-8 Delta-17 ithy acid desaturase 2.12 0.73 CNO_4008 CNAG_0126.1 SPS 1901 2-deoxy-Diuconate 3-dehydrogenase, 4.61 0.73 CNO_4008 CNAG_0262.1 YMR099C Aldose 1-epimenase 2.17 0.73 CNO_1898 CNAG_0892.41 SUCZ Invertase, sucrose-hydrolyzing enzyme 4.85 0.69 CNO_1899 CNAG_0892.41 SUCZ Invertase, sucrose-hydrolyzing enzyme 4.85 0.69 CNO_1890 CNAG_0892.41 SUCZ Invertase, sucrose-hydrolyzing enzyme 4.85 0.69 CNO_1890 CNAG_0892.41 SUCZ Invertase, sucrose-hydrolyzing enzyme 1.189 0.69 CNO_1890 CNAG_0892.41 SUCZ Invertase, sucrose-hydrolyzing enzyme 4.85 0.69 CNO_180 CNAG_0892.41 CNAG_0892.41 SUCZ | | | CNO_6216 | CNAG_03834.1 | SUR2 | Sphinganine hydroxylase | 3.94 | 3.49 | | 5.51 |
| CNO_1991 CNAG_00126.1 CNBB3600-B Detato 7 tity acid desturates 2.17 0.73 CNO_1991 CNAG_00126.1 SP51901 2-decoxyD-gluconate 3-delydrogenase, 461 0.73 0.73 CNO_1991 CNAG_00126.1 YMR099C Aldose 1-epimerase 2.17 0.73 CNO_1991 CNAG_0022.1 YMR099C Aldose 1-epimerase 4.85 0.73 CNO_1898 CNAG_0692.3.1 CNR(356) Glucose-fructose oxidoreductase 4.85 0.69 CNO_1898 CNAG_0692.3.1 CNR(356) Glucose-fructose oxidoreductase 4.85 0.69 CNO_1898 CNAG_0692.1 CNR(356) Glucose-fructose oxidoreductase 4.85 0.69 CNO_1899 CNAG_0692.1 CNR(356) Glycopan phosphate phosp | | | CNO_5772 | CNAG_04757.1 | YBL095W | Putative thioesterase | 8.21 | 0.17 | u u | |
| CNO_1991 CNAG_00126.1 2-deoxy-D-gluconate 3-dehydrogenase, purative 461 0.73 CNO_1991 CNAG_0252.1 YMR099C Addoze 1-epimerase 2.17 0.73 CNO_1891 CNAG_0262.1 YMR099C Glucose-fructose oxidoreductase 4.85 0.69 CNO_1892 CNAG_06924.1 CNR3600 Glucose-fructose oxidoreductase 1.87 0.69 CNO_1892 CNAG_06924.1 CNR3600 Glucose-fructose oxidoreductase 1.87 0.69 CNO_1890 CNAG_06923.1 CNR3600 Glucose-fructose oxidoreductase 1.83 0.69 CNO_1890 CNAG_06923.1 CNR3600 Glucose-fructose oxidoreductase 1.83 0.69 CNO_1890 CNAG_06923.1 CNR3600 Lactonoblydrolase 3.74 0.69 CNO_1802 CNAG_06021 GAL2A Hexose transporter 3.35 0.69 CNO_4708 CNAG_06201 GAL2A Hexose transporter 2.40 1.04 CNO_2332 CNAG_06201 GAL2A Hexose transporter 3.50 1.04 | | | CNO 591 | CNAG 01150.1 | CNBD3600-B | Delta-12 fatty acid desaturase | 2.22 | 2. |) | |
| CNO_1991 CNAG_0262.1 YMR099C Aldose Tepimerase 2.17 CNO_11414 CNAG_06924.1 SUC2 Invertase, sucrose-functose oxidoreductase 4.85 CNO_1888 CNAG_06924.1 SUC2 Invertase, sucrose-functose 11.89 0.69 CNO_1880 CNAG_06924.1 SUC2 Invertase, sucrose-functose 11.89 0.69 CNO_1890 CNAG_0692.3.1 CNAI 3360 Lactonohydrolase 3.74 0.69 CNO_1890 CNAG_0666.1 GHHI Glycosal notices 4.85 2.32 CNO_3028 CNAG_0666.1 GHHI Glycosal transporter 2.22 2.22 CNO_3028 CNAG_0620.1 GAA2A Hexose transporter 2.00 1.09 CNO_4798 CNAG_0620.1 GAA2A Hexose transporter 2.40 0.73 CNO_4329 CNAG_0620.1 GAA2A Hexose transporter 3.00 1.14 CNO_4329 CNAG_0620.1 GAL2A Hexose transporter 3.00 1.14 CNO_4330 CNAG_0620.1 MAG_0620.1 | | | CNO_4008 | CNAG_00126.1 | SPS1901 | 2-deoxy-D-gluconate 3-dehydrogenase, | 4.61 | 0.73 | | |
| CNO_1818 CNAG_0294.1 CNE0800 Glucose-fructose oxidoreductase 4.85 0.69 CNO_1888 CNAG_06924.1 SUCZ Invertase, sucrose-hydrolyzing enzyme 11.89 0.69 CNO_1890 CNAG_06923.1 CNK360 G-phosphate phosphokerolase 11.89 0.69 CNO_1890 CNAG_04783.1 CNISTGO G-phosphate phosphokerolase 3.74 0.69 CNO_3528 CNAG_0676.1 CNATGO Glycogen phosphorylase 4.97 2.32 CNO_3028 CNAG_06290.1 CNAG_1060.0 Glycogen phosphorylase 2.22 1.09 CNO_3028 CNAG_06290.1 CNAG_10620.1 CNAG_1060.0 Glycogen phosphorylase 2.22 CNO_3028 CNAG_06290.1 CNAG_1060.0 Glycogen phosphorylase 2.22 CNO_4329 CNAG_0620.1 CNAG_1060.0 Glycogen phosphorylase 2.60 1.09 CNO_4933 CNAG_0633.1 CNAG_0633.1 CNAG_0634.1 ANTZ-A Hexose transporter 2.40 1.23 CNO_2332 CNAG_0638.1 ANAG_0639.1 ANTZ-A | | Carbohydrate | CNO_1991 | CNAG_02622.1 | YMR099C | Aldose 1-epimerase | 2.17 | | | |
| CNO_1888 CNAG_069241 SUCZ Invertase, sucrose-hydrolyzing enzyme 3.37 0.69 CNO_1890 CNAG_069231 CNR360 6-phosphate/D-fructose 11.89 0.69 CNO_1890 CNAG_069231 CNR1630 b-acronohydrolesce 3.74 0.69 CNO_4708 CNAG_0407.1 CNR3760 Glyozal oxidase 4.85 2.32 CNO_4708 CNAG_0666.1 GPH 1 Glyocagn phosphorylase 4.85 2.32 CNO_4748 CNAG_0666.1 GAL2-A Hexose transporter 3.26 1.09 CNO_4748 CNAG_0620.1 CNAG_0690.1 CNAG_0 | | | CNO 1414 | CNAG 024741 | CNF0800 | Glucose-fructose oxidoreductase | 4 85 | | | |
| CNO_1890 CNAG_069231 CNIX3360 D-sylulose 5-phosphate/D-fungose 11.89 CNO_1890 CNAG_069231 CNIX3360 Lactronohydrolase 3.74 CNO_3708 CNAG_0666.1 GPH 1 Glycoal oxidase 4.85 2.32 CNO_3708 CNAG_0666.1 GPH 1 Glycoal oxidase 4.87 2.32 CNO_3028 CNAG_0666.1 GPH 1 Glycoal oxidase 4.87 2.32 CNO_4708 CNAG_0650.1 CNAG_1009 Glycoal oxidase 4.97 2.32 CNO_4708 CNAG_0650.1 CNAG_1009 Glycoal oxidase 4.97 2.32 CNO_4708 CNAG_06290.1 CNAG_1009 Glycoal oxidase 2.01 1.09 CNO_4709 CNAG_0623.1 CNAG_0623.1 CNAG_0620.1 CNAG_0620.1 1.14 CNO_4709 CNAG_0623.1 HXT2-A Hexose transporter 2.01 1.14 CNO_2332 CNAG_06290.1 GAL2-B Hexose transporter 3.60 1.14 CNO_2349 CNAG_06290.1 GAL2-B Hexose transport | | | CNO 1888 | CNAG 069241 | SUC | Invertase sucrose-hydrolyzing enzyme | 3.37 | 69 0 | | |
| CNO_5766 CNAG_04733.1 CNJ1630 Lactronohydrolase Lactronohydrolase 3.74 CNO_4768 CNAG_0407.1 CNA3760 Glyozgen phosphorylase 4.97 2.32 CNO_4789 CNAG_0666.1 GHH (Glyozgen phosphorylase) 4.97 2.32 CNO_4329 CNAG_0666.1 GAL2-A Hexose transporter 3.36 1.09 CNO_4328 CNAG_06290.1 GAL2-A Hexose transporter 2.60 1.09 CNO_4329 CNAG_06232.1 CNN0500 Sugar transporter 2.40 1.23 CNO_5016 CNAG_06323.1 CNN0500 Sugar transporter 2.01 1.23 CNO_5016 CNAG_06327.1 MAL1106 Hexose transporter 3.80 0.73 CNO_5335 CNAG_06527.1 MAL1106 Hexose transporter 3.50 1.14 CNO_2149 CNAG_06527.1 MAL1106 Hexose transporter 3.50 1.14 CNO_2349 CNAG_06537.1 ADL302 Sugar transporter 3.50 1.04 CNO_4749 CNAG_06537.1 ADL302 | | | CNO_1890 | CNAG_06923.1 | CNK3360 | D-xylulose 5-phosphate/D-fructose | 11.89 | | | |
| CNO_5766 CNAG_04753.1 CNI/630 Lactonohydrolase 3.74 CNO_3659 CNAG_04007.1 CNA3760 Glyoxal oxidase 4.85 2.32 CNO_3559 CNAG_02700.1 GPH 1 Glycosyl transferase 2.22 2.22 CNO_4329 CNAG_02700.1 CNA5050 Plasma membrane H+-pantotherate 2.60 1.09 CNO_4329 CNAG_06323.1 CNA6050 Plasma membrane H+-pantotherate 2.60 1.09 CNO_4329 CNAG_06323.1 CNAG_06323.1 CNA6050 Sugar transporter 2.01 1.23 CNO_5016 CNAG_0818.1 HXT2-A Hexose transporter 2.01 1.14 CNO_5016 CNAG_0820.1 GAL2-B Hexose transporter 2.01 1.13 CNO_516 CNAG_0820.1 AL2-A Hexose transporter 3.00 1.14 CNO_4749 CNAG_0820.1 GAL2-B Hexose transporter 3.00 1.14 CNO_2149 CNAG_0820.1 AL2-B Hexose transporter 3.00 1.64 CNO_2479 CN | | | | | | 6-phosphate phosphoketolase | | | | |
| CNO_4708 CNAG_00407.1 CNA3760 Glyoxal oxidase 4.85 CNO_3559 CNAG_0666.1 Glycogen phosphorylase 4.97 2.32 CNO_4368 CNAG_0666.1 GR12-A Hexose transporter 3.36 1.09 CNO_4329 CNAG_0630.1 GAL2-A Hexose transporter 2.60 1.09 CNO_4329 CNAG_0630.1 GNAE-A Hexose transporter 2.60 1.09 CNO_4329 CNAG_063.1 CNAG_063.1 Hexose transporter 2.40 1.09 CNO_4329 CNAG_0632.1 MAL1106 Hexose transporter 2.40 1.13 CNO_532 CNAG_06327.1 MAL1106 Hexose transporter 3.80 0.73 CNO_5332 CNAG_06527.1 MAL1106 Hexose transporter 3.20 1.14 CNO_5332 CNAG_06527.1 MAL1106 Hexose transporter 3.20 1.14 CNO_2499 CNAG_0659.1 GAL2-B Hexose transporter 3.20 1.14 CNO_2149 CNAG_0659.1 PDC1 Pyruvate decarboxylase | | | CNO_5766 | CNAG_04753.1 | CNJ1630 | Lactonohydrolase | 3.74 | | | |
| CNO_3559 CNAG_0666.1 GPH 1 Glycogen phosphorylase 4.97 2.32 CNO_3028 CNAG_02790.1 CNAG_02790.1 <th></th> <th></th> <td>CNO_4708</td> <td>CNAG_00407.1</td> <td>CNA3760</td> <td>Glyoxal oxidase</td> <td>4.85</td> <td></td> <td></td> <td></td> | | | CNO_4708 | CNAG_00407.1 | CNA3760 | Glyoxal oxidase | 4.85 | | | |
| CNO_3028 CNAG_02790.1 GNC3100 Glycosyl transferase 2.22 CNO_4748 CNAG_06290.1 GAL2-A Hexose transporter 3.36 1.09 CNO_4748 CNAG_06290.1 GAL2-A Hexose transporter 2.60 1.09 CNO_4329 CNAG_0629.1 CNAG_0632.1 CNN0500 Sugar transporter 2.40 1.23 CNO_5016 CNAG_0014.1 HXT2-A Hexose transporter 2.01 1.23 CNO_5016 CNAG_0629.1 AAL1106 Hexose transporter 3.80 0.73 CNO_4349 CNAG_0629.1 GAL2-B Hexose transporter 3.56 1.14 CNO_4449 CNAG_0629.1 GAL2-B Hexose transporter 3.56 1.64 CNO_4449 CNAG_0629.1 DAL502 Sugar transporter 3.69 1.64 CNO_2149 CNAG_0496.1 PDC1 Pyruvate decarboxylase 3.56 1.64 CNO_5289 CNAG_0496.1 ADH4 Alcohol dehydrogenase 3.21 3.80 CNO_4057 CNAG_0497.1 | | | CNO_3559 | CNAG_06666.1 | GPH1 | Glycogen phosphorylase | 4.97 | 2.32 | 1.7 | |
| CNO_4748 CNAG_06290.1 GAL2-A Hexose transporter 3.36 1.09 CNO_4329 CNAG_06323.1 CNA5050 Plasma membrane H+-pantothenate 2.60 1.09 CNO_4329 CNAG_06323.1 CNN0500 Sugar transporter 2.40 1.03 CNO_4933 CNAG_06323.1 CNN0500 Sugar transporter 2.01 1.23 CNO_2332 CNAG_06321.1 HXT2-A Hexose transporter 3.80 0.73 CNO_2332 CNAG_06527.1 MAL1106 Hexose transporter 3.70 1.14 CNO_4749 CNAG_06290.1 GAL2-B Hexose transporter 3.56 1.14 CNO_4749 CNAG_06291 GAL2-B Hexose transporter 3.56 1.14 CNO_4749 CNAG_06291 GAL2-B Hexose transporter 3.56 1.14 CNO_2149 CNAG_04659.1 DAL502 Sugar transporter 3.09 1.64 CNO_2564 CNAG_04659.1 ADH4 Alcohol dehydrogenase 3.21 3.80 CNO_4077 CNAG_06432.1 | | | CNO_3028 | CNAG_02790.1 | CNC3100 | Glycosyl transferase | 2.22 | | | |
| CNO_4329 CNAG_00540.1 CNA5050 Plasma membrane H+-pantothenate 2.60 1.09 CNO_4933 CNAG_06323.1 CNN6500 Sugar transporter 2.40 1.23 CNO_5016 CNAG_00114.1 HXT503-A Sugar transporter 2.01 1.23 CNO_5016 CNAG_06227.1 MAL1106 Hexose transporter 3.80 0.73 CNO_2363 CNAG_06290.1 GAL2-B Hexose transporter 3.70 1.14 CNO_2149 CNAG_06290.1 GAL2-B Hexose transporter 3.56 1.64 CNO_2149 CNAG_06291.1 DAL502 Sugar transporter 3.09 1.64 CNO_2149 CNAG_0659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2149 CNAG_04659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2309 CNAG_06490.1 ADH4 Alcohol dehydrogenase 2.43 1.02 CNO_4071 CNAG_06432.1 CNB1 Apocytochrome b 2.75 2.75 CNO_7071 N/A | | Sugar uptake | CNO_4748 | CNAG_06290.1 | GAL2-A | Hexose transporter | 3.36 | | | |
| CNO_4933 CNAG_06323.1 CNN0500 Sugar transporter 2.40 CNO_5016 CNAG_00114.1 HXT503-A Sugar transporter 2.01 1.23 CNO_2332 CNAG_003438.1 HXT2-A Hexose transporter 3.80 0.73 CNO_2345 CNAG_06227.1 MAL1106 Hexose transporter 3.70 1.14 CNO_2149 CNAG_0629.1 GAL2-B Hexose transporter 3.56 1.13 CNO_2149 CNAG_0459.1 DAL502 Sugar transporter 3.09 1.64 CNO_2149 CNAG_04659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2149 CNAG_04659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2309 CNAG_04659.1 ADH4 Alcohol dehydrogenase 16.05 1.02 CNO_4071 CNAG_06432.1 CNN1520 Putative acetate kinase 2.43 2.43 CNO_4857 CNG_06432.1 COB1 Apocytochrome b 2.75 2.05 CNO_7076 N/A COB1 A | | | CNO_4329 | CNAG_00540.1 | CNA5050 | Plasma membrane H+-pantothenate symporter | 2.60 | 1.09 | | |
| CNO_2316 CNAG_00114.1 HXT503-A Sugar transporter 2.01 1.23 CNO_2332 CNAG_03438.1 HXT2-A Hexose transporter 3.80 0.73 CNO_2365 CNAG_06227.1 MAL1106 Hexose transporter 3.70 1.14 CNO_2149 CNAG_0620.1 GAL2-B Hexose transporter 3.56 1.13 CNO_2149 CNAG_01946.1 DAL502 Sugar transporter 3.09 1.64 CNO_2149 CNAG_04659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2309 CNAG_04659.1 ADH302 Alcohol dehydrogenase 16.05 1.02 CNO_4071 CNAG_06432.1 CNN 1520 Putative acetate kinase 2.43 3.80 CNO_4857 CNG_0432.1 CNB1 Apocytochrome b 2.75 2.75 CNO_7076 N/A COB1 Apocytochrome b 2.70 2.70 CNO_7075 N/A CNB NABD5 NABD4 dehydrogenase subunit 5 2.65 CNO_3030 CNAG_06940.1 COX1 </th <th></th> <th></th> <td>CNO_4933</td> <td>CNAG_06323.1</td> <td>CNN0500</td> <td>Sugar transporter</td> <td>2.40</td> <td></td> <td></td> <td></td> | | | CNO_4933 | CNAG_06323.1 | CNN0500 | Sugar transporter | 2.40 | | | |
| CNO_2332 CNAG_03438.1 HXT2-A Hexose transporter 3.80 0.73 CNO_3635 CNAG_06227.1 MAL1106 Hexose transporter 3.70 1.14 CNO_4749 CNAG_06290.1 GAL2-B Hexose transporter 3.56 1.64 CNO_2149 CNAG_01946.1 DAL502 Sugar transporter 3.09 1.64 CNO_2149 CNAG_04659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2309 CNAG_04659.1 ADH302 Alcohol dehydrogenase 16.05 1.02 CNO_4071 CNAG_06432.1 CNN1520 Putative acetate kinase 2.43 3.80 CNO_4857 CNAG_06432.1 CNB1 Apocytochrome b 2.75 2.75 CNO_7076 N/A COB1 Apocytochrome b 2.75 2.70 CNO_7075 N/A NABD5 NABH dehydrogenase subunit 5 2.65 CNO_3030 CNAG_06940.1 COX1 Cytochrome oxidase subunit 1 2.32 | | | CNO_5016 | CNAG_00114.1 | HXT503-A | Sugar transporter | 2.01 | 1.23 | | |
| CNO_3635 CNAG_06227.1 MAL1106 Hexose transporter 3.70 1.14 CNO_4749 CNAG_06290.1 GAL2-B Hexose transporter 3.56 1.64 CNO_2149 CNAG_04659.1 DAL502 Sugar transporter 3.09 1.64 CNO_2369 CNAG_04659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2309 CNAG_04659.1 ADH302 Alcohol dehydrogenase 16.05 1.02 CNO_4071 CNAG_06432.1 CNN1520 Putative acetate kinase 2.43 3.80 CNO_4857 CNG_0432.1 CNB1 Apocytochrome b 2.75 2.75 CNO_6796 N/A COB1 Apocytochrome b 2.75 2.70 CNO_7071 N/A COB1 Apocytochrome b 2.70 2.70 CNO_3030 CNAG_06940.1 COX1 Cytochrome oxidase subunit 1 2.32 | | | CNO_2332 | CNAG_03438.1 | HXT2-A | Hexose transporter | 3.80 | 0.73 | | |
| CNO_2149 CNAG_06220.1 GAL2-B Hexose transporter 3.56 CNO_2149 CNAG_04659.1 DAL502 Sugar transporter 3.09 1.64 CNO_2149 CNAG_04659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2309 CNAG_02489.1 ADH302 Alcohol dehydrogenase 16.05 1.02 CNO_4071 CNAG_00197.1 ADH4 Alcohol dehydrogenase 2.43 3.80 CNO_4857 CNAG_06432.1 CNN1520 Putative acetate kinase 2.43 2.75 CNO_6796 N/A COB1 Apocytochrome b 2.75 2.70 CNO_7071 N/A COB1 Apocytochrome b 2.70 2.70 CNO_7056 N/A NAB5 NABD4 dehydrogenase subunit 5 2.65 CNO_3030 CNAG_06940.1 COX1 Cytochrome oxidase subunit 1 2.32 | | | CNO_3635 | CNAG_06527.1 | MAL1106 | Hexose transporter | 3.70 | 1.14 | | |
| CNO_2149 CNAG_01946.1 DAL502 Sugar transporter 3.09 1.64 CNO_5864 CNAG_04659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2309 CNAG_02489.1 ADH302 Alcohol dehydrogenase 16.05 1.02 CNO_4071 CNAG_06432.1 CNN1520 Putative acetate kinase 2.43 3.80 CNO_4857 CNAG_06432.1 CNN1520 Putative acetate kinase 2.75 2.75 CNO_6796 N/A COB1 Apocytochrome b 2.75 2.70 CNO_7071 N/A COB1 Apocytochrome b 2.70 2.70 CNO_7056 N/A NAB5 NABH dehydrogenase subunit 5 2.65 2.65 CNO_3030 CNAG_06940.1 COX1 Cytochrome oxidase subunit 1 2.32 | | | CNO_4749 | CNAG_06290.1 | GAL2-B | Hexose transporter | 3.56 | , | | |
| CNO_5684 CNAG_04659.1 PDC1 Pyruvate decarboxylase 9.53 1.13 CNO_2309 CNAG_02489.1 ADH302 Alcohol dehydrogenase 16.05 1.02 CNO_4071 CNAG_06432.1 ADH4 Alcohol dehydrogenase 2.43 3.80 CNO_4857 CNAG_06432.1 CNN1520 Putative acetate kinase 2.43 2.75 CNO_6796 N/A COB1 Apocytochrome b 2.75 2.70 CNO_7071 N/A COB1 Apocytochrome b 2.70 2.70 CNO_7056 N/A NAB5 NADH dehydrogenase subunit 5 2.65 2.65 CNO_3030 CNAG_06940.1 COX1 Cytochrome oxidase subunit 1 2.32 | | | CNO_2149 | CNAG_01946.1 | DAL502 | Sugar transporter | 3.09 | 1.64 | | |
| CNO_2309 CNAG_02489.1 ADH302 Alcohol dehydrogenase 16.05 1.02 CNO_4071 CNAG_00197.1 ADH4 Alcohol dehydrogenase 3.21 3.80 CNO_4857 CNAG_06432.1 CNN1520 Putative acetate kinase 2.43 3.80 CNO_6796 N/A COB1 Apocytochrome b 2.75 2.75 CNO_7071 N/A COB1 Apocytochrome b 2.70 2.70 CNO_7056 N/A NAD5 NADH dehydrogenase subunit 5 2.65 2.65 CNO_3030 CNAG_06940.1 COX1 Cytochrome oxidase subunit 1 2.32 | | Glycolysis/ fermentation | CNO_5684 | CNAG_04659.1 | PDC1 | Pyruvate decarboxylase | 9.53 | 1.13 | 2.6 | |
| CNO_4071 CNAG_00197.1 ADH4 Alcohol dehydrogenase 3.21 CNO_4857 CNAG_06432.1 CNN1520 Putative acetate kinase 2.43 CNO_6796 N/A COB1 Apocytochrome b 2.75 CNO_7071 N/A COB1 Apocytochrome b 2.70 CNO_7056 N/A NAD5 NADH dehydrogenase subunit 5 2.65 CNO_3030 CNAG_06940.1 COX1 Cytochrome oxidase subunit 1 2.32 | | | CNO_2309 | CNAG_02489.1 | ADH302 | Alcohol dehydrogenase | 16.05 | 1.02 | 3.8 | |
| CNO_4857 CNAG_06432.1 CNN1520 Putative acetate kinase CNO_6796 N/A COB1 Apocytochrome b CNO_7071 N/A COB1 Apocytochrome b CNO_7056 N/A NAD5 NADH dehydrogenase subunit 5 CNO_3030 CNAG_06940.1 COX1 Cytochrome oxidase subunit 1 | | | CNO_4071 | CNAG_00197.1 | ADH4 | Alcohol dehydrogenase | 3.21 | 3.80 | | |
| CNO_6796 N/A COB1 Apocytochrome b CNO_7071 N/A COB1 Apocytochrome b CNO_7056 N/A NAD5 NADH dehydrogenase subunit 5 CNO_3030 CNAG_06940.1 COX1 Cytochrome oxidase subunit 1 | | | CNO_4857 | CNAG_06432.1 | CNN1520 | Putative acetate kinase | 2.43 | | | |
| N/A COB1 Apocytochrome b N/A NAD5 NADH dehydrogenase subunit 5 CNAC_06940.1 COX1 Cytochrome oxidase subunit 1 | | Mitochondrial | CNO_6796 | N/A | COB1 | Apocytochrome b | 2.75 | | | |
| N/A NAD5 NAD1 denydrogenase subunit 5 CNAC_06940.1 COX1 Cytochrome oxidase subunit I | | | CNO_7071 | A/X | COB1 | Apocytochrome b | 2.70 | | | |
| CNAG_00940.1 COXI Cytochrome oxidase subunit I | | | CNO_/056 | N/A | NAD5 | NADH dehydrogenase subunit 5 | 2.65 | | | |
| | | | | | | | 7:77 | | | |

| | ; | : | - | , | ; | | : | : | |
|----------------------|---------------------------|-------------------------------|---------------------|--------------|--|-------------------------|-------------------------|-----------------------|--------------------|
| i ranscript Class | Functional | Microarray Oligo Number | Broad Annotation | Gene Name | Putative Function | C. neorormans -/+ O2 | 5. cerevisiae -/+ 02 | C. albicans -/+ 02 | 5. pombe -/+ 02 |
| | | CNO_7059 | CNAG_26848.1 | АТР9 | ATP synthase subunit 9 | 2.88 | | | |
| | | CNO_7070 | N/A | NAD5 | NADH dehydrogenase subunit 5 | 2.84 | | | |
| | | CNO_7072 | N/A | NAD1 | NADH dehydrogenase subunit 1 | 2.78 | | | |
| | | CNO_4032 | CNAG_00162.1 | AOX1 | Alternative oxidase | 11.10 | | | |
| | | CNO_4991 | CNAG_06446.1 | MSS51 | Probable initiation factor specific for translation of COX1 mRNA | 2.56 | 0.66 | | |
| | Amino acid metabolism | CNO_5592 | CNAG_04942.1 | MET101-A | Potential uroporphyrin-3 C-methyltransferase | 4.02 | 0.79 | | 2.01 |
| | | CNO_7085 | CNAG_07036.1 | MET102 | Potential uroporphyrin-3 C-methyltransferase | 3.19 | 0.79 | | 2.01 |
| | | CNO_157 | CNAG_04535.1 | LYS1202 | Isocitrate/isopropylmalate dehydrogenase | 2.33 | 0.83 | | |
| | | CNO_5826 | CNAG_04835.1 | CNJ0860 | Dihydrodipicolinate synthase | 3.68 | | | |
| | Stress | CNO_4133 | CNAG_00296.1 | HSP104 | Putative chaperonin; heat shock protein | 6.94 | 0.94 | | |
| | | CNO_2955 | CNAG_01750.1 | SSA4 | Heat shock protein 70-kDa protein 7 | 3.26 | 0.88 | 1.6 | |
| | | CNO_2714 | CNAG_03347.1 | HSP78 | Chaperonin hsp78 | 2.98 | 1.43 | 2.5 | |
| | | CNO_1131 | CNAG_06106.1 | SIS102 | Type II HSP40 co-chaperone that interacts with the HSP70 protein Seath | 2.21 | 1.00 | | |
| | | CNO 3302 | CN AG 01464 1 | VHB1 | Flavohemodlobin | 2073 | 0.20 | | |
| | | CNO 2594 | CNAG 03228.1 | CNG1310 | Putative stress-related protein | 3.86 | 2.5 | | |
| | | CNO_3384 | CNAG_02799.1 | DAK202-A | Dihydroxyacetone kinase isoenzyme l | 3.67 | 1.35 | | |
| | | CNO_1796 | CNAG_02484.1 | CPR101 | Cyclophilin type peptidyl-prolyl <i>cis-trans</i> isomerase | 5.39 | 0.91 | | |
| Down-Regulated | Vesicle | CNO_2480 | CNAG_03286.1 | ERP2 | Involved in endoplasmic reticulum to | 0.50 | 1.09 | | |
| Transcripts | trafficking | | | | Golgi transport and localized to COPII- coated vesicles | | | | |
| | | CNO_3038 | CNAG_02817.1 | SEC4 | Secretory vesicle-associated Rab GTPase | 0.49 | 0.95 | | |
| | | CNO_610 | CNAG_01175.1 | GOT1 | Protein of unknown function, may be involved in endonlessmic retirulum Goldi transport | 0.48 | 1.13 | | |
| | | 0130 010 | 1 71 CCO 2017 1 | A DA4101 | Despetable destructions and the material AD47 | 0.40 | 130 | | |
| | | CNO 2507 | CNAG 03251.1 | ARF202 | ADP-ribosylation factor | 0.38 | 0.94 | | |
| | | CNO_5924 | CNAG_04779.1 | PEP7 | Multivalent adaptor protein, facilitates | 0.36 | 1.15 | | |
| | | | | | high-fidelity vesicle docking and fusion | | | | |
| | | CNO_1355 | CNAG_06048.1 | CNM0500 | Golgi protein involved in vesicular transport that interacts with GTPases | 0.45 | | | |
| | Ribosomal/ translation | CNO_3027 | CNAG_02714.1 | EFB1 | Elongation factor 1 beta | 0.49 | 1.16 | | |
| | | CNO_2495 | CNAG_03263.1 | TUF1 | Elongation factor Tu | 0.48 | 0.48 | | |
| | | CNO_3147 | CNAG_02948.1 | SUP45 | Eukaryotic peptide chain release factor subunit 1 | 0.46 | 1.06 | | |
| | | CNO 5912 | CNAG 04770.1 | EMG1 | Ribosome biogenesis protein | 0.50 | 0.96 | | |
| | | CNO_4882 | CNAG_06468.1 | NOG1 | Putative GTPase required for 60S ribosomal | 0.40 | 1.20 | | |
| | | CNO 614 | CNAG 01168 1 | CBES | subunit biogenesis Beaudouridina evathasa catalytic subunit | 0.37 | 0.75 | | |
| | | | | 5 | of box H/ACA small nucleolar ribonucleo- protein particles | | | | |
| | | CNO_780 | CNAG_01395.1 | RKI1 | Ribose-5-phosphate ketol-isomerase, involved | 0.46 | 0.68 | | |
| | | | | | in ribosome biogenesis | | | | |
| | | CNO_5077 | CNAG_05465.1 | ASC1 | WD repeat protein (G-beta-like protein) involved in translation regulation | 0.45 | 0.89 | | |
| | | CNO_1781 | CNAG_02234.1 | RPL6B | 60S ribosomal protein L6 | 0.48 | 0.86 | | |
| | | | | | | | | | |

Table 1. Continued.

| Table 1. Continued. | ntinued. | | | | | | | | |
|----------------------------|------------------------|-------------------------------|---------------------|--------------|---|-------------------------|-------------------------|-----------------------|---------------------------|
| Transcript Class | Functional Category | Microarray Oligo Number | Broad Annotation | Gene Name | Putative Function | C. neoformans -/+ 02 | S. cerevisiae -/+ 02 | C. albicans -/+ 02 | 5. <i>pombe</i> -/+ 02 |
| | | 1010 | 00000 | | | Ç | | | |
| | | CNO_2181 | CNAG_01990.1 | KPS5 | Probable 40's ribosomal protein 55 | 0.47 | 0.88 | | |
| | | CNO_2148 | CNAG_019/6.1 | RPLZ3B | 6US fibosomal protein LZ3 | 0.4/ | 0.83 | | |
| | | CNO_300/ | CINAG_04799.1 | Art 145 | Fucative IIDOSOIII protein E14 | 7.70 | 10.9 | | |
| | | CNO_3164 | CNAG_05232.1 | RPI 2B | ous ribosomal protein is Ribosomal protein i 8 | 0.45 | 0.87 | | |
| | | CNO_1023 | CNAG_01224.1 | RPL18A-A | Ribosomal protein L18 | 0.45 | 1.09 | 1.5 | |
| | | CNO_4638 | CNAG_00640.1 | RPS4A | 40s ribosomal protein s4 | 0.41 | 0.91 | | |
| | Sterol | CNO_5444 | CNAG_05117.1 | OSH6 | Probable involvement in ergosterol | 0.48 | 1.18 | | |
| | metabolism | | | | biosynthesis | | | | |
| | | CNO_6194 | CNAG_03819.1 | ERG6 | Putative sterol methyltransferase | 0.50 | 1.86 | | |
| | Stress | CNO_5555 | CNAG_04981.1 | CTA102 | Catalase | 0.30 | 1.48 | 3.6 | |
| | | CNO_4399 | CNAG_00575.1 | CTA101 | Catalase | 0.15 | 1.48 | 3.6 | |
| | Cell wall | CNO_1838 | CNAG_02071.1 | BNI4 | Localized to the bud neck, required for | 0.47 | 1.23 | | |
| | synthesis | | | | localization of chitin synthase III to the bud neck | | | | |
| | | CNO_798 | CNAG_00914.1 | KRE601 | Putative beta-glucan synthase | 0.36 | 1.34 | | |
| | | CNO_1904 | CNAG_06898.1 | CHS7 | Protein of unknown function, involved | 0.49 | 1.12 | | |
| | | | | | in chitin biosynthesis | | | | |
| | | CNO_693 | CNAG_00888.1 | CNB1 | Calcineurin B regulatory subunit | 0.45 | 0.97 | | |
| | | CNO_570 | CNAG_01164.1 | GFA1-B | Putative glutamine:fructose-6-phosphate | 0.43 | 0.74 | | |
| | | | | | amidotransferase | | | | |
| | | CNO_294 | CNAG_04320.1 | CNH2170 | Cellubiuronic acid synthase | 0.43 | | | |
| | Capsule | CNO_4475 | CNAG_00701.1 | CNA6610 | CAP64, capsule-associated protein | 0.48 | | | |
| | synthesis | | | | | | | | |
| | | CNO_4393 | CNAG_00600.1 | CNA5640 | CAP60, capsule-associated protein | 0.46 | | | |

Shown are a selection of categories of genes that are up-regulated or down-regulated by *C. neoformans* in response to hypoxia. Data shown are a ratio of transcript levels from wild-type cells grown in hypoxia to those grown in normoxia. For comparison, data are also shown (where available, N/A, not available. doi:10.11), and 5. pombe [13]. Broad annotation for these genes are included, where available. N/A, not available.

Α.

| Genes up-regulated in WT in response to hypoxia | 183 |
|--|-----|
| Genes for which STRONGER induction is seen in $Sre1\Delta-1$ than in WT | 35 |
| Genes for which WEAKER induction is seen in $Sre1\Delta-1$ than in WT | 7 |
| Genes down-regulated in WT in response to hypoxia | 135 |
| Genes for which STRONGER repression is seen in $Sre1\Delta-1$ than in WT | 0 |
| Genes for which WEAKER repression is seen in $Sre1\Delta-1$ than in WT | 12 |




Figure 5. Microarray Hybridization and RT-QPCR Studies Demonstrate That a Subset of Genes Involved in the Hypoxia Response Require Sre1 for Their Regulation

(A) Summary of profiling transcriptional response to hypoxia in $sre1\Delta$ and wild-type (WT) cells. cDNA from wild-type cells cultivated in normoxic conditions was hybridized against cDNA from wild-type cells exposed to hypoxic conditions on arrays containing 6,846 features from the genome of *C. neoformans*. Similarly, cDNA from $sre1\Delta$ -1 grown in normoxia was hybridized against cDNA from $sre1\Delta$ -1 grown in hypoxia. Statistical analysis of the resulting arrays was conducted using the software SAM. The transcriptional response to hypoxia in wild-type was identified as the set of genes with statistically significant changes in gene expression as determined by SAM. A cutoff of 2-fold or greater changes in gene expression was imposed upon this gene set to determine the number of genes up- and down-regulated in wild-type in response to hypoxia. The arrays hybridized with cDNA from $sre1\Delta$ -1 were compared to those hybridized with wild-type cDNA to determine which hypoxia-induced transcriptional changes were significantly different between $sre1\Delta$ -1 and wild-type. The resulting gene set is summarized above, where relative degree of induction/repression in $sre1\Delta$ -1 and wild-type were compared by dividing fold-change in expression in $sre1\Delta$ -1 with fold-change in expression in wild-type.

(B) RT-QPCR. cDNA from *sre1*∆-1 and wild-type cells grown in normoxia and hypoxia were amplified using primers against *ERG1*, *ERG3*, *ERG5*, and *ACT1*. Values obtained for *ERG1*, *ERG3*, and *ERG5* were normalized against *ACT1* for each sample to give relative expression, and then expression for the three genes were normalized to their expression in wild-type in normoxic conditions. Error bars represent standard deviation across four samples. doi:10.1371/journal.ppat.0030022.g005


type with a knockout mutant in SXII, a gene involved in cell identity and sexual differentiation that is not expressed in non-mating cells and is dispensable for virulence [26,27]. In these control experiments, $sxiI\Delta$ represented $\sim 50\%$ of the cells in the inoculum and $\sim 50\%$ of the cells recovered from the various tissues.


In the intranasal competition experiments, animals were sacrificed 21 d post-infection and the proportion of mutant cells in the lungs was determined. Again, knockout mutants in SRE1, SCP1, STP1, and TCO1 showed a significant and reproducible defect in their ability to proliferate in the lungs relative to wild-type cells (Figure 6B). A control infection using a 1:1 mixture of wild-type and $sxi1\Delta$ showed equal proliferation between wild-type and mutant. We also performed a co-infection using a mixture of wild-type and a knockout mutant in LAC1, which encodes for the laccase primarily responsible for melanin synthesis (Figure 6B). As previously reported, the $lac1\Delta$ mutant, which is completely defective in melanization (Figure 3C), displayed normal proliferation in the lungs [28].

A role for Tco1 in virulence was established previously using an intranasal inoculation assay [22]. To assess the role of

SREBP pathway components in virulence, we inoculated eight to ten animals per strain by tail vein injection with two independently generated knockout mutants in *SRE1*, *SCP1*, and *STP1*, and monitored the mice for progression to severe morbidity. As shown in Figure 6C, each of the mutants displayed a similar and significant decrease in virulence. Thus, like the Tco1 pathway, the SREBP pathway plays a demonstrable role in pathogenesis.

Azole antifungals are perhaps the most widely used agents for the treatment of fungal infections worldwide. They are thought to act solely as inhibitors of lanosterol- 14α -demethylase, encoded in *S. cerevisiae* by *ERG11*, another oxygendependent enzyme in the ergosterol biosynthetic pathway. Our microarray analysis suggested a role for Srel in activating transcription of genes encoding several oxygendependent enzymes of this pathway, whereas Tcol was dispensable. If these effects were relevant to growth, mutants in the Srel pathway should be sensitive to fluconazole treatment. Indeed, we found that mutation of *SRE1*, *STP1*, or *SCP1* results in a dramatic increase in sensitivity to fluconazole under normoxic conditions: $\sim 100 \times$ lower concentrations of fluconazole were required to inhibit their








Figure 6. Hypoxia-Sensitive Mutants Display Proliferation and Virulence Defects

(A) Tail vein inoculation competition experiments. Approximately 1:1 mixtures of wild-type (WT) and the indicated mutant (marked with a NAT resistance gene) were injected into mice (A/J) intravenously via the tail vein $(2\times10^6$ total cells/mouse). The actual proportion of mutant cells in each inoculum were determined by plating a dilution of the inoculum on nonselective medium and then assaying 100-200 individual colonies for NAT resistance. At 10 d post-infection, animals were sacrificed and the lungs, brains, and spleen from each animal were homogenized and serial dilutions were plated. Then, 100-200 colonies per organ were assayed for NAT resistance to determine the percentage of mutant cells. Error bars represent the standard deviation from four mice per inoculum. (B) Intranasal inoculation competition experiments. Approximately 1:1

mixtures of wild-type and the indicated mutant were inoculated intranasally into mice (A/J) (5 \times 10 5 total cells/mouse). The actual proportions of mutant cells were determined as in (A). At 21 d post-infection, animals were sacrificed and the lungs from each animal were treated as in (A). Error bars represent the standard deviation from four mice per inoculum.

(C) Virulence assays. Eight to ten mice (A/J) were injected intravenously via the tail vein with 2×10^5 cells of the indicated strain and progression to severe morbidity was monitored.

doi:10.1371/journal.ppat.0030022.g006

growth compared with concentrations required for wild-type growth inhibition (Figure 7). In contrast, a knockout mutant of *TCO1* displayed a sensitivity that was identical to that of wild-type.

Fungal pathogens require molecular oxygen for the biosynthesis of several molecules, making hypoxic host tissues an inhospitable environment. Using the obligate aerobic human pathogen C. neoformans as a model, we have identified two pathways that are required for hypoxic adaptation and virulence. We show that an SREBP-like pathway in C. neoformans is activated by hypoxia, is required for hypoxic adaptation, and controls the expression of oxygen-dependent enzymes in the ergosterol biosynthetic pathway. The Sre1 pathway acts in parallel with a pathway controlled by the histidine kinase homolog Tco1 in hypoxic adaptation. Importantly, analysis of mutants clearly demonstrates both are required for pathogen growth/survival in experimental animals and for virulence, which strongly suggests a link between hypoxic adaptation and pathogenesis. The simplest interpretation of our data is that the pathogen experiences hypoxia in the host to which it must adapt in order to cause disease.

Other pathways are also likely to play a role in hypoxic adaptation. For example, transcription of OLE1, which encodes for a $\Delta 9$ -fatty acid desaturase in S. cerevisiae, is regulated in a manner that shows remarkable parallels to the Srel pathway. In response to low levels of oxygen or unsaturated fatty acids, a proteolytic cleavage event releases the putative transcription factor Mga2 from the endoplasmic reticulum membrane, allowing up-regulation of OLE1 transcription [29]. Indeed, our microarray data shows that OLE1 is




Figure 7. Mutants in the SREBP Pathway, but Not the $tco1\Delta$ Mutant, Display Hypersensitivity to Fluconazole

Cells (10^4 cells/ml) of wild-type and each mutant strain were cultured in YNB for three d in 96-well format in the presence of 0.0045–30 μ g/ml fluconazole, after which relative growth was assessed using OD₆₀₀ measurements. Data shown are an average of at least three independent cultures for each strain. Error bars represent standard deviations. doi:10.1371/journal.ppat.0030022.g007

up-regulated in C. neoformans in response to hypoxia in an Sre1-independent manner.

Although our results show that hypoxia-sensitive mutants in two distinct pathways are defective in virulence, it is conceivable that the dual requirement for the Sre1 and Tco1 pathways in virulence reflects defects other than hypoxic adaptation in the corresponding mutants. However, our data argue that the requirement for these pathways cannot be explained by a trivial defect for either pathway for growth in minimal medium at 37 °C (Figure 3A). Furthermore, the mutants do not display gross defects in capsule formation, and they display phenotypes during murine infection distinct from those defective in the production of two other virulence factors, melanin and urease [28,30]. Specifically, while SREBP pathway mutants display a slight defect in melanin formation, their reduced growth in the lungs of mice infected intranasally contrasts to that of $lac1\Delta$ mutants, which are completely defective in melanization yet display normal proliferation in the lungs both in published work [28] and in our hands (Figure 6B). Likewise, mutants defective in urease activity have been reported to not display a defect in proliferation in the lungs [30], in contrast to the effects of $sre1\Delta$ and $tco1\Delta$ mutants reported here. While distinct from mutants defective in melanin and urease production, the tissue proliferation/survival profiles of SREBP and Tco1 pathway mutants are similar to each other (Figure 6), consistent with a common mechanism underlying their virulence defects.

For each mutant strain tested, we observed a greater folddefect in the lungs compared with that in the brain or spleen. At least two explanations could account for these observations. First, the hypoxic conditions within the lungs could be more severe than in the brain or spleen, perhaps due to the fact that the lungs are a predominant site of inflammation. The influx of large numbers of activated macrophages into the lungs may generate a locally hypoxic microenvironment that is more challenging than those of the brain or spleen. Alternatively, turnover rate of *C. neoformans* may be greater in the lungs than in the brain and spleen, which would amplify any per-division growth differences between wild-type and mutant strains. Assuming similar steady-state levels of organisms, higher turnover would require both a higher growth rate of C. neoformans in the lungs as well as a greater degree of killing than in the non-lung tissues. Further studies will be required to distinguish between these possibilities.

The remarkable sensitivity of Srel pathway mutants to fluconazole is relevant for two reasons. First, it suggests that the effectiveness of antifungals that target ergosterol biosynthesis may in part be aided in vivo by the sensitivity of ergosterol synthesis to hypoxic conditions. This model may explain observations in otherwise puzzling reports showing that while fluconazole blood levels typically only reach 10-20 μg/ml, successful treatment of C. albicans isolates that display in vitro resistance towards fluconazole (MIC $> 50 \mu g/ml$) can be achieved in a substantial fraction of cases [31]. It may be that hypoxic conditions in vivo lower the effective concentration of the drug required to clear the infection. Second, our data suggest that if inhibitors of the Sre1 pathway could be developed, they would strongly synergize with ergosterol pathway inhibitors such as azoles in the treatment of cryptococcal infections.

Materials and Methods

Strains and media. C. neoformans serotype A strain H99 (a kind gift of J. K. Lodge) was used as wild-type. Strains were grown in rich medium, YPD (1% yeast extract, 2% Bacto-peptone, 2% glucose, 0.015% L-tryptophan, 0.004% adenine) or minimal medium, YNB (0.45% yeast nitrogen base w/o amino acids w/o ammonium sulfate, 1.5% ammonium sulfate, 2% glucose). The strains used in this study are listed in Table S1.

Strain engineering. The wild-type H99 strain was transformed using biolistic techniques as previously described [32]. The genespecific deletion constructs were generated with the primers listed in Table S2 using overlap fusion PCR. Specifically, the nourseothricin (NAT) resistance (natR) cassette was amplified from plasmids derived from pHL001 using the primers 5'NAT-10 and 3'NAT-10. This cassette was targeted to delete specific genes by fusing the cassette to the genomic sequences flanking the target gene. These flanking sequences were amplified from H99 genomic DNA by PCR using the ***-W1 and ***-W3 primers to amplify a ~1-kb region 5' to the target gene and the ***-W4 and ***-W6 primers to amplify a ~1-kb region 3' to the target gene. The two flanking regions and the natR cassette were fused into one product using PCR and biolistically transformed. Transformants were selected on YPD agar plates containing 100 μg/ml NAT. sre1Δ-1 was generated using the CN4363 set of primers and deletes a portion of SRE1, including the DNAbinding domain. sre1Δ-2 was generated using the CDS_5817 set of primers and deletes all of SRE1. scp1 Δ -1 was generated using the CN1329 set of primers and deletes a portion of SCP1 that includes transmembrane domains. scp1Δ-2 was generated using the CDS_2788 set of primers and deletes all of SCP1. $stp1\Delta-1$ and $stp1\Delta-2$ were both generated using the CDS_3547 set of primers, which deletes all of STP1. $stp1\Delta-1$ and $stp1\Delta-2$ were independently generated in separate biolistic transformations. $tco1\Delta$ -1 was generated using the CN1538 set of primers and deletes all but ~200 bp at the 5' end of the open reading frame (ORF). $tco1\Delta$ -2 was generated using the CDS_3015 set of primers and deletes all of TCO1. sxi1 Δ was generated using the CN5693 set of primers and $lac1\Delta$ was generated using the CN2897 set of primers. Both of these deletions result in a complete deletion of the gene. Strains referred to as complete deletions may leave intact small portions of the 5' or 3' ends of the ORF due to ambiguities in the annotation, but are not likely to retain any function. The recombination events were verified by PCR using the ***-V5 and VER-5-3 primers to detect the 5' integration event and the ***-V3 and VER-3-2 primers to detect the 3' integration event. The $tco1\Delta sre1\Delta$ double mutant was generated by using a neomycin (NEO) resistance (neoR) cassette which was amplified from the plasmid pJAF1 using the primers 5'NAT-10 and 3'NEO-10. The neoR cassette was fused to flanks generated using the CDS_5817 set of primers. This knockout construct was then transformed into the tco1Δ-1 strain. Transformants were selected on YPD agar plates containing 200 µg/ml G418.

As a redundant test to confirm the phenotypes of independent disruptants, the $sre1\Delta$ -2 and $tco1\Delta$ -1 mutants were complemented by biolistically transforming the knockout strains with two linear DNA constructs simultaneously. The first construct restored SRE1 or TCO1 to its original locus, replacing the natR cassette which had been used to disrupt the gene. The second construct inserted a neoR cassette ~300 bp upstream of the start of the SRE1 ORF, or ~1,100 bp upstream of the start of the TCO1 ORF. Specifically, in order to complement sre1Δ-2, the primers CDS_5817-W1 and CDS_5817-W6 were used to amplify the SRE1 ORF from H99 genomic DNA, including 1 kb of upstream and downstream sequence, creating the first transformation construct. The second transformation construct was generated using overlap fusion PCR. The primers C_p5817-W1h and C_p5817-W3 were used to generate the ~1-kb region downstream of the neoR insertion site, and the primers C_CPR202-W4 and C_CPR202-3F were used to amplify the ~1-kb region upstream of the neoR insertion site. These two flanking regions were fused to the neoR cassette, which was amplified as above, creating the second transformation construct. In order to complement $tco1\Delta$ -1, the primers CDS_3015-W1 and CDS_3015-W6 were used to amplify the TCO1 ORF from H99 genomic DNA, including 1 kb of upstream and downstream sequence, creating the first transformation construct. The second transformation construct was generated using overlap fusion PCR. The primers C_p3015-W1 and C_p3015-W3 were used to generate the \sim 1-kb region downstream of the neoR insertion site, and the primers C_p3015-W4 and C_p3015-W6 were used to amplify the ~ 1 -kb region upstream of the neoR insertion site. These two flanking regions were fused to the neoR cassette, creating the second transformation construct. $sre1\Delta-2$ and $tco1\Delta-1$ were

biolistically transformed with both constructs simultaneously, and transformants were selected on YPD agar plates containing 200 µg/ml G418. Positive transformants were patched onto YPD agar plates containing 200 µg/ml G418 and then replica-plated onto YPD agar plates containing 100 µg/ml NAT. Colonies that were resistant to G418 and sensitive to NAT were screened using PCR for the presence of the complete SRE1 or TCO1 ORF. The phenotypes of complemented strains are shown in Figure S1.

Generation of the 3×FLAG-tagged SRE1 strain. Three copies of the FLAG epitope plus linker sequence (REQKLEL-3×FLAG-GSGSGS) were inserted between A313 and A314 of Sre1 just upstream of the predicted DNA-binding domain. Insertion of the 3×FLAG construct was performed by biolistically transforming H99 with two linear DNA constructs simultaneously. The first construct targeted the natR cassette for insertion \sim 300 bp upstream of the start of the SRE1 ORF, just downstream of the adjacent gene. The second construct targeted the 3×FLAG sequence for insertion into the SRE1 ORF but did not contain any resistance marker. Both constructs were generated using overlap fusion PCR. Specifically, the natR cassette was amplified as described above. The primers C_5817-W1FLg and C_5817-W3 were used to amplify the $\sim 1,300$ -bp region between the site of insertion of the natR cassette and the site of insertion for the 3×FLAG sequence. The primers C_CPR202-W4 and C_CPR202-3F were used to amplify the \sim 1-kb region upstream of the *natR* insertion site. These two flanking regions were fused to the natR cassette using overlap PCR to create one of the two transformation constructs. The 3×FLAG sequence was amplified by PCR from the p3FLAG-KanMX [33] plasmid using the primers C_5817-FLAGFg and C_5817-FLAGRg. C_5817-W1Flg and C_5817-W3 were again used to amplify the upstream flanking region between the 3×FLAG insertion site and the natR insertion site, and the primers C_5817-5FgFl and C_5817-5Re were used to amplify the ~1-kb region downstream of the 3×FLAG insertion site. These two flanks were fused to the 3×FLAG cassette using overlap PCR to create the second transformation construct. After biolistic transformation with both constructs simultaneously and selection for NAT resistance, transformants were screened for insertion of the 3×FLAG sequence by PCR using the primers _5817V5Fle and C__5817-FLAGFg.

Hypoxic cultivation. Strains were grown in YPD at 37 °C. Normoxic conditions were considered general atmospheric levels within the lab ($\sim 21\%$ O₂). For hypoxic conditions, two systems were employed. One system consisted of a controlled atmosphere chamber (855-AC; Plas-Labs, http://www.plas-labs.com) maintained at 37 °C and kept at below 0.2% oxygen levels utilizing a gas mixture containing 5% CO₂, 10% H₂, 85% N₂ in combination with palladium catalyst. While the hydrogen-palladium mixture eliminated most oxygen within the chamber, the architecture of the chamber did allow a small amount of oxygen to slowly enter the chamber, allowing for C. neoformans cultivation (as it is an obligate aerobe). Oxygen levels within the controlled atmosphere chamber were monitored using a QRAE Plus oxygen detector (RAE Systems, http://www.raesystems.com). Low oxygen (and not high CO2) was the most likely source of the phenotypes presented in this paper, as all strains grew normally in atmospheric conditions that were supplemented with $5\%~\mathrm{CO_2}$ (Figure S2). The second system utilized a gas mixture containing 0.2% O₂, 0.25% CO₂, 99.55% N₂ that was bubbled through sterile pipettes into medium contained in silicon-stoppered flasks arranged in parallel. The gas mixture was humidified prior to being bubbled into the medium by first bubbling through sterile water to minimize

For growth plate phenotypes, cultures grown in YPD at 37 °C were diluted to $\mathrm{OD}_{600~\mathrm{nm}} = 0.6$ in water, then diluted 10-fold in series prior to being spotted onto YPD agar plates. Plates were then cultured in the dark in normoxic or in the controlled atmosphere chamber in hypoxic conditions.

For the growth curve, cultures were grown overnight in liquid YNB medium and diluted to $\mathrm{OD}_{600~\mathrm{nm}} = 0.085$ in YNB. These were then cultured at 37 °C in a roller drum. At the indicated time intervals, cell density was assessed via OD₆₀₀ readings. Data shown are an average of three independent experiments and error bars represent their standard deviations.

Capsule assay. C. neoformans strains were grown in liquid YPD cultures overnight at 30 °C. The cultures were then diluted 1/100 in either Sabouraud medium (non-inducing conditions) or 10% Sabouraud medium buffered to pH 7.3 with 50 mM MOPS (capsule-inducing conditions) and grown at 30 °C for 3 d. An equal volume of culture and India ink were mixed and the capsule was visualized using bright-field microscopy at 160× magnification using an Axiovert 200M (Zeiss, http://www.zeiss.com) microscope running Axiovision software. To quantitate capsule size, the cell diameter and

capsule diameter of at least 30 cells per strain under capsule-inducing conditions were measured using the Axiovision software. Statistical analysis was by Student's t-test.

Melanization assays. Cultures grown overnight in YPD medium were spotted onto melanin-inducing plates containing L-DOPA (Ldihydroxyphenylalanine, 100 mg/l; Sigma, http://www.sigmaaldrich. com) and grown for 3-5 d in the dark at 37 °C.

Isolation of total RNA. Log-phase cultures were grown aerobically in YPD at 37 °C, with shaking, to an $OD_{600~nm}=0.6$, at which point the cultures were split into two. For hypoxic growth, cells were collected by centrifugation and then resuspended while in the controlled atmosphere chamber with 50 ml of YPD medium that had been previously deoxygenated by >2 h incubation with agitation in chamber. For normoxic growth, cultures were maintained in atmospheric conditions. Following 2 h of hypoxic treatment, both normoxic and hypoxic cultures were collected by centrifugation at 4 °C. Cell pellets were flash frozen in liquid nitrogen and lyophilized prior to total RNA extraction using TRIzol Reagent (Invitrogen, http://www.invitrogen.com) following manufacturer's instructions. RNA samples were treated with DNase I (Roche, http://www.roche. com) for 30 min at 37 °C, followed by two extractions with chloroform, precipitation in isopropanol, and resuspension in DEPC-treated water

Microarray-based genome-wide transcriptional profiling. Total RNA was reverse transcribed by priming with oligo dT and utilizing aminoallyl-dUTP. The resultant cDNA was then coupled to Cy3- and Cy5-labeled probes (Amersham Biosciences, http://www.amersham biosciences.com), and hybridized to microarrays printed on site, containing 6,846 70-mer oligonucleotides corresponding to C. neoformans ORFs from the serotype A genome as annotated by our laboratory (http://cryptogenome.ucsf.edu). Labeled cDNA from wildtype grown in normoxic conditions was hybridized against cDNA from wild-type grown in hypoxic conditions; cDNA from sre1∆-1 grown in normoxia was hybridized against sre1∆-1 grown in hypoxia; cDNA from tco1Δ-1 grown in normoxia was hybridized against tco1Δ-1 grown in hypoxia; and cDNA from sre1\Delta-2 grown in normoxia was hybridized against wild-type grown in normoxia. Data for each strain represents four independent experiments and includes two dyeswaps. Arrays were scanned on an Axon 400B scanner with GenePix software (Axon Instruments, http://www.moleculardevices.com) and the images generated were analyzed using SpotReader software (Niles Scientific, http://www.nilesscientific.com) for spot identification and flagging. Array signals were bulk-normalized and filtered for flagged spots using NOMAD (available at http://ucsf-nomad.sourceforge.net). Data were log-transformed (base 2) and filtered for genes that contained data for at least three out of four arrays from each strain, and missing values were calculated through K-nearest neighbor algorithm using Significance Analysis of Microarrays (SAM) software [34] prior to statistical analysis by SAM. The class of genes up- and down-regulated in wild-type was determined in a one-class response test based on the arrays hybridized with cDNA from wild-type. Genes were defined as being significantly regulated in wild-type if they were scored by SAM as significant with a median false discovery rate (FDR) of less than 8% and if their expression changed by at least 2-fold or greater. For comparison of the differences in transcriptional response to hypoxia in wild-type and mutant, a two-class response test was employed, comparing the arrays hybridized with wild-type cDNA to either the $sre1\Delta-1$ arrays or the $tco1\Delta-1$ arrays. All SAM analysis employed an FDR of less than 8%. The comparison between wild-type and tco1∆-1 arrays at this FDR did not return any genes with statistically significant differences between the two strains. The data from the set of genes returned from the comparison between wildtype and $sre1\Delta-1$ were averaged across the four arrays per strain, and the average fold-change in expression in $sre1\Delta-1$ was divided by the average fold-change in expression in wild-type for each gene. For the set of genes up-regulated by wild-type in response to hypoxia, if this value was greater than 1, the gene was defined as having stronger induction in $sre1\Delta$ -1 than in wild-type, whereas if the value was less than 1, the gene was defined as having weaker induction in $sre1\Delta-1$ than in wild-type. For the set of genes down-regulated by wild-type in response to hypoxia, if this value was greater than 1, the gene was defined as having weaker repression in $sre1\Delta$ -1 than in wild-type, and if the value was less than 1, the gene was defined as having stronger repression in $sre1\Delta$ -1 than in wild-type. Statistically significant genes identified by SAM with 2-fold or greater changes in expression are listed in Tables S3 and S4 in Supporting Information.

Gene naming conventions. We refer to the generic names described by the Stanford B-3501 serotype D genome annotation. These are in the form CNXY, where X indicates the chromosome (A for Chromosome I, B for Chromosome II, etc.) and Y indicates the

gene position. In addition, if a gene has a homolog in *S. cerevisiae* with a BLASTP expect value of less than 10^{-4} , we refer to it by the name of the best *S. cerevisiae* homolog. In cases where the same gene in *S. cerevisiae* was the closest homolog to multiple genes in *C. neoformans*, two digits were added to the end of the *S. cerevisiae* name to generate unique specific names (e.g., *SPS1901* is one *C. neoformans* gene homologous to the *S. cerevisiae* gene *SPS19*) (E.Chow, O. Liu, and S. O'Brien, unpublished data).

RT-QPCR. Microarray results were confirmed utilizing RT-QPCR. cDNA was synthesized from the same DNase I-treated total RNA that was used for microarray analysis using Superscript III Reverse Transcriptase (Invitrogen) and oligo dT primers. Approximately 0.2 ng of cDNA was used as template in a QPCR reaction containing SYBR Green dye (Molecular Probes, http://probes.invitrogen.com). Fluorescent signal was measured on an Opticon DNA Engine PCR machine (MJ Research, http://www.bio-rad.com). For each primer set, standard curves were generated using 5-fold sequential dilutions of cDNA to account for differences in priming efficiencies. For each sample, values obtained were normalized to the levels of actin (ACTI). Data shown are averages of the four independent samples, and are normalized to the levels of transcript present on average in wild-type under normoxic conditions. The following primers were used: for ERG1, C_ERG1-3-5 and C_ERG1-5-5; for ERG3, C_ERG3-3-5 and C_ERG3-5-5; for ERG5, C_ERG5-3-1 and C_ERG5-5-1; for ACTI, C_ACTI-1 and C_ACTI-2.

Immunoblotting. Strains containing FLAG-SRE1 as the sole allele were grown to $OD_{600 \text{ nm}} = 0.4$ in 100 ml YPD at 37 °C. For the normoxic growth sample, half the culture was then harvested. For hypoxic growth, the remaining culture was spun down and the cell pellet was then resuspended in 50 ml YPD medium that had been previously de-oxgenated for >2 h by the bubbling of gas (a mixture containing 0.2% O₂, 0.25% CO₂, 99.55% N₂) through sterile pipettes into the medium contained in silicon stopper-sealed flasks. The cultures were then cultivated in the presence of bubbling gas mixture for an additional 2 h before harvesting. Both normoxic and hypoxic cultures were pelleted by centrifugation, and following a wash with cold water, were flash frozen in liquid nitrogen and lyophilized. The lyophilized cells were lysed in 24 mM NaOH and 1% (v/v) βmercaptoethanol on ice for 30 min, and proteins were precipitated with 6.4% trichloracetic acid while on ice. After centrifugation, the protein pellet was washed once with acetone, dried, and then resuspended in HU buffer (200 mM phosphate buffer [pH 6.8], 8M urea, 5% SDS, 1 mM EDTA, 100 mM DTT, bromophenol blue) and loaded onto a bis-Tris gel. Following SDS-PAGE, the fractionated proteins were transferred to nitrocellulose membrane (MSI Nitrobind membrane; Fisher Scientific, https://www1.fishersci.com). Immunoblotting was performed using mouse anti-FLAG IgG (Sigma) and rabbit anti-PSTAIRE IgG (Santa Cruz Biotechnology, http:// www.scbt.com), which were recognized by horseradish peroxidaseconjugated goat anti-mouse IgG and goat anti-rabbit IgG secondary antibodies (Bio-Rad, http://www.bio-rad.com), respectively. Visualization was performed utilizing SuperSignal West Pico Chemiluminescent Substrate (Pierce, http://www.piercenet.com).

Intravenous co-infection experiments. C. neoformans strains were individually grown in liquid YPD cultures overnight at 30 °C. Cells were counted using a hemacytometer and an equal number of wildtype cells and cells of the co-infecting strain were combined. The cells were washed twice in PBS and resuspended in PBS to a final concentration of 2×10^7 cells/ml. Then, 5-6 wk-old female A/J (National Cancer Institute [NCI]) mice were anesthetized with inhaled isoflurane, and 100 μ l of the inoculum (2 × 10⁶ total cells) was injected via tail vein. Four mice were infected per inoculum. A dilution of each inoculum was also plated on Sabouraud agar plates containing 40 μg/ml gentamicin and 50 μg/ml carbenicillin. The plates were incubated for 2 d at 30 °C, colonies were counted to verify the concentration of cells in the inoculum, and the proportion of mutant cells in the inoculum was determined by assaying 100-200 colonies for NAT resistance on YPD agar plates containing 100 μg/ml NAT. Mice were sacrificed by CO₂ inhalation followed by cervical dislocation 10 d post-infection, and the lung, brain, and spleen were removed and homogenized in 5 ml sterile PBS. Serial dilutions of each organ sample were plated on Sabouraud agar plates containing 40 μg/ml gentamicin and 50 μg/ml carbenicillin. The plates were incubated for 2 d at 30 °C, colonies were isolated, and the proportion of mutant cells within each organ was determined by assaying 100-200 colonies for NAT resistance on YPD agar plates containing 100 μg/ml NAT.

Intranasal co-infection experiments. Inocula were prepared as in the intranvenous co-infection experiments except cells were resuspended in PBS to a final concentration of 1×10^7 cells/ml. Then, 4-5 wk-

old female A/J (NCI) mice were anesthetized by intraperitoneal injection of ketamine (75 mg/kg) and medetomidine (0.5–1.0 mg/kg). The mice were then suspended from a silk thread by their front incisors and 50 μ l of the inoculum (5 \times 10 5 cells) were slowly pipetted into the nares. After 10 min, the mice were lowered and the anesthesia was reversed by intraperitoneal injection of atiplamezole (1.0–2.5 mg/kg). Four mice were infected per inoculum. The concentrations of the inocula and the proportions of mutant cells in the inocula were determined as in the intravenous co-infection experiments. After 21 d post-infection, the animals were sacrificed by $\rm CO_2$ inhalation followed by cervical dislocation and the lungs were analyzed as in the intravenous co-infection experiments.

Mouse virulence studies. Inocula were prepared as in the intravenous-co-infection experiments, except cells were resuspended in PBS to a final concentration of 2×10^6 cells/ml. Then, 5–6 week-old female A/J (NCI) mice were an esthetized with inhaled isoflurane and $100~\mu$ l of the inoculum $(2\times 10^5~{\rm cells})$ were injected via the tail vein. The concentration of cells in the inoculum was confirmed by plating serial dilutions. Mice were monitored several times a week until onset of symptoms (weight loss, ruffled fur, abnormal gait) and then monitored daily. Mice that displayed signs of severe morbidity (weight loss, abnormal gait, hunched posture, swelling of the cranium) were sacrificed by CO_2 inhalation followed by cervical dislocation.

Fluconazole sensitivity assay. Strains were cultured overnight in YNB medium at 30 °C, spun down, washed once in PBS, and then resuspended in YNB to a concentration of 104 cells/ml. This resuspension was aliquoted into 96-deep well plates at a volume of 500 μl/well. To this, 100 μl of fluconazole (Sigma; stock solution of 1 mg/ml prepared in dimethyl sulfoxide [DMSO] and subsequently diluted in YNB) was added to give final fluconazole concentrations ranging from 0.0046 to 30 µg/ml. The plates were cultured for 48 h at 30 °C with shaking (1,000 rpm), at which point measurements were taken on a spectrophotometer. For each culture, 100 μl of YNB was added to one well instead of fluconazole. The OD_{600} reading for this well was set to a value of one, and growth in all other wells for that culture were normalized to that reading. For each strain, appropriate dilutions of DMSO without fluconazole were added to a series of cultures as a negative control. Growth with DMSO for all strains at all concentrations tested was similar to growth without DMSO (unpublished data).

Supporting Information

Figure S1. Complementation of Hypoxia-Sensitivity and Melanization Phenotypes $sre1\Delta$ and $tco1\Delta$ Strains by Homologous Targeting of the Corresponding Wild-Type Genes

(A) SREI was re-introduced into its endogenous locus in $sre1\Delta-2$ and TCOI was re-introduced into its endogenous locus in $tcoI\Delta-I$. Cultures diluted to $OD_{600\mathrm{nm}}=0.6$ were diluted serially in 10-fold increments prior to being spotted onto YPD plates. Plates were incubated in normoxic or hypoxic (controlled atmosphere chamber; less than 0.2% oxygen) conditions in the dark at 37 °C.

(B) Melanin assays. The indicated strains were grown to saturation and spotted onto L-DOPA–containing medium. The plates were then cultured at $37\,^\circ\mathrm{C}$ in the dark.

Found at doi:10.1371/journal.ppat.0030022.sg001 (4.1 MB PDF).

Figure S2. Knockout Mutants in SREBP Pathway Components and in *TCO1* Are Not Sensitive to High Levels of Carbon Dioxide

Cultures diluted to $\rm OD_{600nm}=0.6$ were diluted serially in 10-fold increments prior to being spotted onto YPD plates. Plates were incubated in the dark at 37 °C in normal atmospheric conditions or in air supplemented with 5% $\rm CO_2$ (NuAire IR Autoflow $\rm CO_2$ Water-Jacketed Incubator, http://www.nuaire.com).

Found at doi:10.1371/journal.ppat.0030022.sg002 (7.9 MB PDF).

Table S1. Strains Used in This Study

Found at doi:10.1371/journal.ppat.0030022.st001 (38 KB DOC).

Table S2. Primers Used in This Study

Found at doi:10.1371/journal.ppat.0030022.st002 (114 KB DOC).

Table S3. Microarray Dataset

Found at doi:10.1371/journal.ppat.0030022.st003 (103 KB XLS).

Table S4. Sre1-Regulated Genes in Hypoxia

Found at doi:10.1371/journal.ppat.0030022.st004 (35 KB XLS).



Table S5. Sre1-Regulated Genes in Normoxia Found at doi:10.1371/journal.ppat.0030022.st005 (15 KB XLS).

Accession Numbers

Microarray data described in this paper has been submitted to the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo) under accession number GSE6226. The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html) accession number for the sequences discussed in this paper are as follows: Stanford B-3501 serotype D genome (AAEY00000000); Sre1 homologs from *C. albicans* (AAK69672), human (SREBP-1A, NP_001005291), *S. pombe* (CAB52036), and *Ustilago maydis* (XP_761868); and Tco1 homologs from *B. dermatiditis* (ABF13477), *C. albicans* (BAA24952), and *Neurospora crassa* (AAB03698). Where GenBank accession numbers were not available, we have provided annotation by the Broad Institute of MIT and Harvard (http://www.broad.mit.edu): *C. neoformans* Scp1 (Broad locus CNAG_01580.1), Sre1 (Broad locus CNAG_04804.1), Stp1 (Broad locus CNAG_05742.1), and Tco1 (Broad locus

References

- Erecinska M, Silver IA (2001) Tissue oxygen tension and brain sensitivity to hypoxia. Respir Physiol 128: 263–276.
- Carlsson PO, Palm F, Andersson A, Liss P (2001) Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 50: 489–495.
- Studer L, Csete M, Lee SH, Kabbani N, Walikonis J, et al. (2000) Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci 20: 7377–7383.
- Nau R, Bruck W (2002) Neuronal injury in bacterial meningitis: Mechanisms and implications for therapy. Trends Neurosci 25: 38–45.
- Sawyer RG, Spengler MD, Adams RB, Pruett TL (1991) The peritoneal environment during infection. The effect of monomicrobial and polymicrobial bacteria on pO2 and pH. Ann Surg 213: 253–260.
- Bartolini E, Frigimelica E, Giovinazzi S, Galli G, Shaik Y, et al. (2006) Role of FNR and FNR-regulated, sugar fermentation genes in *Neisseria meningitidis* infection. Mol Microbiol 60: 963–972.
- Wood GE, Khelef N, Guiso N, Friedman RL (1998) Identification of Btrregulated genes using a titration assay. Search for a role for this transcriptional regulator in the growth and virulence of *Bordetella pertussis*. Gene 209: 51–58.
- Aly S, Wagner K, Keller C, Malm S, Malzan A, et al. (2006) Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol 210: 208-205.
- Rizzi M, Schindelin H (2002) Structural biology of enzymes involved in NAD and molybdenum cofactor biosynthesis. Curr Opin Struct Biol 12: 709–720.
- 10. Panek H, O'Brian MR (2002) A whole genome view of prokaryotic haem biosynthesis. Microbiology 148: 2273–2282.
- Setiadi ER, Doedt T, Cottier F, Noffz C, Ernst JF (2006) Transcriptional response of *Candida albicans* to hypoxia: Linkage of oxygen sensing and Efglp-regulatory networks. J Mol Biol 361: 399–411.
- Doedt T, Krishnamurthy S, Bockmuhl DP, Tebarth B, Stempel C, et al. (2004) APSES proteins regulate morphogenesis and metabolism in *Candida albicans*. Mol Biol Cell 15: 3167–3180.
- Todd BL, Stewart EV, Burg JS, Hughes AL, Espenshade PJ (2006) Sterol regulatory element binding protein is a principal regulator of anaerobic gene expression in fission yeast. Mol Cell Biol 26: 2817–2831.
- Hughes AL, Todd BL, Espenshade PJ (2005) SREBP pathway responds to sterols and functions as an oxygen sensor in fission yeast. Cell 120: 831–842.
- Espenshade PJ (2006) SREBPs: Sterol-regulated transcription factors. J Cell Sci 119: 973–976.
- Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, et al. (1997) Nonfilamentous C. albicans mutants are avirulent. Cell 90: 939–949.
- Idnurm A, Bahn YS, Nielsen K, Lin X, Fraser JA, et al. (2005) Deciphering the model pathogenic fungus *Cryptococcus neoformans*. Nat Rev Microbiol 3: 753–764.
- Hakim JG, Gangaidzo IT, Heyderman RS, Mielke J, Mushangi E, et al. (2000) Impact of HIV infection on meningitis in Harare, Zimbabwe: A prospective study of 406 predominantly adult patients. AIDS 14: 1401–1407.

CNAG $_01850.1$); and H. capsulatum ortholog to Tco1 (Broad locus HCAG $_4501.1$).

Acknowledgments

We thank J. Lodge for strain H99, *natR* cassettes, and instruction on knockout methodology. We thank A. Alspaugh for the *neoR* cassette. We thank Jeff Cox for critical reading of the manuscript.

Author contributions. CDC, OWL, and HDM conceived and designed the experiments, analyzed the data, and wrote the paper. CDC and OWL performed the experiments.

Funding. This work was supported by a grant from the National Institute of Allergy and Infectious Disease to HDM. (R01AI065519). CDC is supported by a National Science Foundation graduate fellowship. OWL is supported by a Howard Hughes Medical Institute predoctoral fellowship.

Competing interests. The authors have declared that no competing interests exist.

- Bicanic T, Harrison TS (2004) Cryptococcal meningitis. Br Med Bull 72: 99– 118
- Kim JB, Spotts GD, Halvorsen YD, Shih HM, Ellenberger T, et al. (1995) Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain. Mol Cell Biol 15: 2582– 9588
- Lane S, Zhou S, Pan T, Dai Q, Liu H (2001) The basic helix-loop-helix transcription factor Cph2 regulates hyphal development in *Candida albicans* partly via TEC1. Mol Cell Biol 21: 6418–6428.
- Bahn YS, Kojima K, Cox GM, Heitman J (2006) A unique fungal twocomponent system regulates stress responses, drug sensitivity, sexual development, and virulence of *Cryptococcus neoformans*. Mol Biol Cell 17: 3122–3135.
- Nemecek JC, Wuthrich M, Klein BS (2006) Global control of dimorphism and virulence in fungi. Science 312: 583–588.
- Hulko M, Berndt F, Gruber M, Linder JU, Truffault V, et al. (2006) The HAMP domain structure implies helix rotation in transmembrane signaling. Cell 126: 929–940.
- 25. Kwast KE, Lai LC, Menda N, James DT 3rd, Aref S, et al. (2002) Genomic analyses of anaerobically induced genes in *Saccharomyces cerevisiae*: Functional roles of Rox1 and other factors in mediating the anoxic response. J Bacteriol 184: 250–265.
- Hull CM, Cox GM, Heitman J (2004) The alpha-specific cell identity factor Sxilalpha is not required for virulence of *Cryptococcus neoformans*. Infect Immun 72: 3643–3645.
- Hull CM, Davidson RC, Heitman J (2002) Cell identity and sexual development in *Cryptococcus neoformans* are controlled by the mating-typespecific homeodomain protein Sxi1alpha. Genes Dev 16: 3046–3060.
- Noverr MC, Williamson PR, Fajardo RS, Huffnagle GB (2004) CNLAC1 is required for extrapulmonary dissemination of *Cryptococcus neoformans* but not pulmonary persistence. Infect Immun 72: 1693–1699.
- Martin CE, Oh CS, Jiang Y (2006) Regulation of long chain unsaturated fatty acid synthesis in yeast. Biochim Biophys Acta. E-pub 13 July 2006.
- Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, et al. (2004) Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol 164: 1761–1771.
- Pfaller MA, Diekema DJ, Sheehan DJ (2006) Interpretive breakpoints for fluconazole and *Candida* revisited: A blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19: 435–447.
- Davidson RC, Cruz MC, Sia RA, Allen B, Alspaugh JA, et al. (2000) Gene disruption by biolistic transformation in serotype D strains of *Cryptococcus neoformans*. Fungal Genet Biol 29: 38–48.
- Gelbart ME, Rechsteiner T, Richmond TJ, Tsukiyama T (2001) Interactions
 of Isw2 chromatin remodeling complex with nucleosomal arrays: Analyses
 using recombinant yeast histones and immobilized templates. Mol Cell Biol
 21: 2098–2106.
- 34. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116–5121.

